Plant-Based Biologics Market By Clinical Trial (Phase I, Phase II, Others); By Source (Tobacco, tobacco cells, tobacco leaves, Nicotiana benthamiana leaves, Carrot cell culture, Rice seeds, Moss, Algae, Duckweed Leafy Biomass, Others); By Product (Taliglucerase alfa, ZMApp, PRX-102, HAI-05, Others); By Diseases (HIV/AIDS, Ebola virus, Cholera, Leprosy, Tuberculosis, Fabry Disease, Anthrax, Pompe Disease, Influenza (Type A, Type B, Type c), Alzheimer, Respiratory Syndromes, Gaucher disease, Cancer, Others); By Mode of Administration (Intramuscular, Oral Administration, Others); By End Users (Hospitals, Clinics, Primary Care Centers, Others);By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020-2028

Report ID :AMI-791 | Category : Healthcare & IT | Published Date : January, 2021 | Pages : 402 | Format :PDF

Industry Trends

Diseases have been affecting human civilizations since time immemorial. The global disease burden cost billions of dollars in revenue. Companies around the globe, both private and public, are increasingly trying to reduce the impact of diseases on human beings by developing both therapeutic and diagnostic biologics. Biologics, also called as biological drugs, is a product which is derived from living organisms, or contains some components of living organisms. Traditionally, animal-based biologics have been used for the treatment of diseases. Gelatin, for instance, is a partially hydrolysed collagen which is derived from bovine or porcine living organisms. Gelatin forms the basis of numerous capsule shells, and is also being used as a stabilizing agent in pharmaceutical products such as vaccines. However, religious practices and concerns regarding the humane treatment of animals for developing animal-based vaccines are prompting researches to move towards plant-based biologics. Furthermore, plant-based biologics are also economical to produce on a large scale, as compared to animal-based products. Also, these products have been proven to be effective agents in controlling pathogens, making it suitable for use as food additives. Bacterial colicins, for instance, is derived from plants. Studies show that they can be used as a food additive for keeping food pathogenic bacteria at bay. Such factors are driving the adoption of plant-based biologics market. Escherichia coli strains, which causes food poisoning in human beings, are eliminated in the presence of these colicins in lower concentrations. The cost of manufacturing a gram of processed colicins is around US$ 1, which makes it viable for commercial use on a large scale. The U.S. Food and Drug Administration Agency has approved the use of these colicins in food products. Compared to the mammalian cell culture processes which are in use currently, plant-based biologics can be produced at a higher pace and greater quantity, without compromising on quality and efficiency. The rising demand for cost-effective drugs and food additives with minimal side effects, coupled with concerns regarding animal abuse for the development of drugs, is paving way for the growth of the global plant-based biologics market.

The COVID-19 pandemic has severely impacted the lives of individuals across the globe. Researches and academicians are increasingly trying to come up with innovative products which can tackle coronavirus. The mutation of the COVID-19 virus is raising concerns regarding the effectiveness of vaccines for controlling the spread of the virus. Plant-based biologics are being touted as a viable alternative for increasing the immunity in individuals, thereby making them more capable in fighting coronavirus. Furthermore, plant-based vaccines are also in development. Texas-based iBio, Inc., for instance, is focussing on the development of therapeutics and vaccines with plant-based products. ACE2-Fc is a COVID-19 therapeutic which is being developed by iBio, in partnership with Planet Biotech. Also, a couple of vaccines named IBIO-200 and IBIO-201 are in the final stages of development. IBIO-201 is based on a process that combines the antigens from SARS-CoV-2 spike protein and iBio's LicKM molecule which helps in enhancing immune response in human beings. LicKM technology which is being used by iBio also has the potential of reducing vaccine antigen dose requirements in all age groups, thereby making it cost effective. Hence, the COVID-19 pandemic is expected to have a positive impact on the global plant-based biologics market in the coming years.

Global plant-based biologics market is anticipated to grow at a CAGR of 26.45% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

Source Outlook:

Tobacco and algae-based biologics are expected to show considerable growth during the forecast years in the global plant-based biologics market. The ease of cultivating tobacco leaves, and the rapid growth potential of algae is expected to lead the adoption of these products for the production of plant-based drugs. Studies by researchers based in the University of California show that algae could be used for the manufacturing of targeted cancer drugs due to the presence of chloroplasts. Immunotoxins from Chlamydomonas reinhardtii, a green alga, has the potential of inhibiting the growth of human B-cell tumours. Researchers are increasingly exploring plant-based drugs for the treatment and prevention of cancer in individuals, and the tumour destroying capabilities in algal drugs are expected to help in the fight against cancer.

Region Outlook:

Based on the regions, North America accounted for the highest share in the global plant-based biologics market in 2019. The presence of numerous plant-based biologics manufacturers, coupled with higher investment in research and development of plant-based therapeutic products from a university level in the U.S. and Canada is a major reason for the higher share of North America in the global plant-based biologics market. In the U.S., for instance, Fraunhofer Center for Molecular Biotechnology, a research center based in Delaware recently completed phase 1 clinical trials for a plant-based vaccine for combating Bacillus anthracis, which is a bacterium that is responsible for causing Anthrax in adults. Companies in the U.S. are also in the process of developing drugs for the treatment of chronic illnesses in individuals. Studies show that over 5 million Americans are suffering from Alzheimer's. By 2050, the number is expected to increase to 14 million. It is the sixth highest cause of death in the U.S. Medicinal plants such as Centella asiatica, Ginkgo biloba, Withania somnifera, etc., are being studied as a possible remedy for curing or slowing the impact of Alzheimer's, thereby helping in bettering the lives of millions of individuals, especially of those over the age of 60 who have a higher risk of being affected by the disease. However, the APAC region is expected to show the highest growth during the forecast years in the global plant-based biologics market. The rising focus on traditional herbs in India, China and Japan, coupled with higher investment in plant-based therapeutics by private companies in these countries is expected to pave way for the growth of the plant-based biologics market in the APAC region. Indian pharmaceutical giant, Sun Pharmaceutical, for instance, received approval for the clinical trial of ACQH, which is a plant-based drug for the treatment of COVID-19 patients. Extracts from a plant named Cocculus hirustus form the base of the proposed COVID-19 drug. Government bodies are increasingly trying to make use of traditional plant-based medicines for the treatment of a range of diseases, as they are more economic for mass commercial use. The plant-based biologics market is expected to see significant investment from government healthcare bodies, which will help in advancing the share of the APAC region in the global plant-based biologics market.

Global Plant-Based Biologics Market Revenue & Forecast, (US$ Million), 2015 – 2028

Competitive Landscape

The report provides both, qualitative and quantitative research of plant-based biologics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the players operating in the plant-based biologics market are Byondis, eleva GmbH, Eversea Inc, iBio, Inc, Icon Genetics GmbH, InVitria, Kentucky BioProcessing, Inc., Leaf Expression Systems, Mapp Biopharmaceutical, Inc., Medicago Inc., OnePointOne, Inc., Pfizer Inc., Planet Biotechnology Inc., PlantForm, Protalix Biotherapeutics, Ventria Bioscience Inc., Zea Biosciences, amongst others.

Global Plant-Based Biologics Market:

By Clinical Trial
- Phase I
- Phase II
- Others
By Source
- Tobacco, tobacco cells, tobacco leaves
- Nicotiana benthamiana leaves
- Carrot cell culture
- Rice seeds
- Moss
- Algae
- Duckweed Leafy Biomass
- Others
By Product
- Taliglucerase alfa
- ZMApp
- PRX-102
- HAI-05
- Others
By Diseases
- HIV/AIDS
- Ebola virus
- Cholera
- Leprosy
- Tuberculosis
- Fabry Disease
- Anthrax
- Pompe Disease
- Influenza
- Type A
- Type B
- Type c
- Alzheimer
- Respiratory Syndromes
- Gaucher disease
- Cancer
- Others
By Mode of Administration
- Intramuscular
- Oral Administration
- Others
By End Users
- Hospitals
- Clinics
- Primary Care Centers
- Others
By Region:
- North America
  - U.S.
  - Canada
  - Mexico
  - Rest of North America
- Europe
  - France
  - The UK
  - Spain
  - Germany
  - Italy
  - Nordic Countries
    - Denmark
    - Finland
    - Iceland
    - Sweden
    - Norway
  - Benelux Union
    - Belgium
    - The Netherlands
    - Luxembourg
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - New Zealand
  - Australia
  - South Korea
  - Southeast Asia
    - Indonesia
    - Thailand
    - Malaysia
    - Singapore
    - Rest of Southeast Asia
  - Rest of Asia Pacific
- Middle East & Africa
  - Saudi Arabia
  - UAE
  - Egypt
  - Kuwait
  - South Africa
  - Rest of Middle East & Africa
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2018

1.2.2. Base Year: 2019

1.2.3. Forecast Years: 2020 – 2028

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Plant-Based Biologics Market

6. Market Synopsis: Plant-Based Biologics Market

7. Plant-Based Biologics Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Plant-Based Biologics Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Plant-Based Biologics Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on Plant-Based Biologics Market

8. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

8.1. Overview

8.1.1. Global Plant-Based Biologics Market Revenue (US$ Mn)

8.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

8.2.1. Phase I

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2015 – 2019

8.2.1.3. Market Forecast, 2020 – 2028

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2015 – 2019

8.2.1.5.1.2. Market Forecast, 2020 – 2028

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2015 – 2019

8.2.1.5.2.2. Market Forecast, 2020 – 2028

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 – 2019

8.2.1.5.3.2. Market Forecast, 2020 – 2028

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 – 2019

8.2.1.5.4.2. Market Forecast, 2020 – 2028

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2015 – 2019

8.2.1.5.5.2. Market Forecast, 2020 – 2028

8.2.2. Phase II

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2015 – 2019

8.2.2.3. Market Forecast, 2020 – 2028

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2015 – 2019

8.2.2.5.1.2. Market Forecast, 2020 – 2028

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2015 – 2019

8.2.2.5.2.2. Market Forecast, 2020 – 2028

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 – 2019

8.2.2.5.3.2. Market Forecast, 2020 – 2028

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 – 2019

8.2.2.5.4.2. Market Forecast, 2020 – 2028

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2015 – 2019

8.2.2.5.5.2. Market Forecast, 2020 – 2028

8.2.3. Others

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2015 – 2019

8.2.3.3. Market Forecast, 2020 – 2028

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2015 – 2019

8.2.3.5.1.2. Market Forecast, 2020 – 2028

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2015 – 2019

8.2.3.5.2.2. Market Forecast, 2020 – 2028

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 – 2019

8.2.3.5.3.2. Market Forecast, 2020 – 2028

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 – 2019

8.2.3.5.4.2. Market Forecast, 2020 – 2028

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2015 – 2019

8.2.3.5.5.2. Market Forecast, 2020 – 2028

8.3. Key Segment for Channeling Investments

8.3.1. By Clinical Trail

9. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

9.1. Overview

9.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

9.2.1. Tobacco, tobacco cells, tobacco leaves

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2015 – 2019

9.2.1.3. Market Forecast, 2020 – 2028

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2015 – 2019

9.2.1.5.1.2. Market Forecast, 2020 – 2028

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2015 – 2019

9.2.1.5.2.2. Market Forecast, 2020 – 2028

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 – 2019

9.2.1.5.3.2. Market Forecast, 2020 – 2028

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 – 2019

9.2.1.5.4.2. Market Forecast, 2020 – 2028

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2015 – 2019

9.2.1.5.5.2. Market Forecast, 2020 – 2028

9.2.2. Nicotiana benthamiana leaves

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2015 – 2019

9.2.2.3. Market Forecast, 2020 – 2028

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2015 – 2019

9.2.2.5.1.2. Market Forecast, 2020 – 2028

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2015 – 2019

9.2.2.5.2.2. Market Forecast, 2020 – 2028

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 – 2019

9.2.2.5.3.2. Market Forecast, 2020 – 2028

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 – 2019

9.2.2.5.4.2. Market Forecast, 2020 – 2028

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2015 – 2019

9.2.2.5.5.2. Market Forecast, 2020 – 2028

9.2.3. Carrot cell culture

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2015 – 2019

9.2.3.3. Market Forecast, 2020 – 2028

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2015 – 2019

9.2.3.5.1.2. Market Forecast, 2020 – 2028

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2015 – 2019

9.2.3.5.2.2. Market Forecast, 2020 – 2028

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 – 2019

9.2.3.5.3.2. Market Forecast, 2020 – 2028

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 – 2019

9.2.3.5.4.2. Market Forecast, 2020 – 2028

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2015 – 2019

9.2.3.5.5.2. Market Forecast, 2020 – 2028

9.2.4. Rice seeds

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2015 – 2019

9.2.4.3. Market Forecast, 2020 – 2028

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2015 – 2019

9.2.4.5.1.2. Market Forecast, 2020 – 2028

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2015 – 2019

9.2.4.5.2.2. Market Forecast, 2020 – 2028

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2015 – 2019

9.2.4.5.3.2. Market Forecast, 2020 – 2028

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2015 – 2019

9.2.4.5.4.2. Market Forecast, 2020 – 2028

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2015 – 2019

9.2.4.5.5.2. Market Forecast, 2020 – 2028

9.2.5. Moss

9.2.5.1. Definition

9.2.5.2. Market Estimation and Penetration, 2015 – 2019

9.2.5.3. Market Forecast, 2020 – 2028

9.2.5.4. Compound Annual Growth Rate (CAGR)

9.2.5.5. Regional Bifurcation

9.2.5.5.1. North America

9.2.5.5.1.1. Market Estimation, 2015 – 2019

9.2.5.5.1.2. Market Forecast, 2020 – 2028

9.2.5.5.2. Europe

9.2.5.5.2.1. Market Estimation, 2015 – 2019

9.2.5.5.2.2. Market Forecast, 2020 – 2028

9.2.5.5.3. Asia Pacific

9.2.5.5.3.1. Market Estimation, 2015 – 2019

9.2.5.5.3.2. Market Forecast, 2020 – 2028

9.2.5.5.4. Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2015 – 2019

9.2.5.5.4.2. Market Forecast, 2020 – 2028

9.2.5.5.5. Latin America

9.2.5.5.5.1. Market Estimation, 2015 – 2019

9.2.5.5.5.2. Market Forecast, 2020 – 2028

9.2.6. Algae

9.2.6.1. Definition

9.2.6.2. Market Estimation and Penetration, 2015 – 2019

9.2.6.3. Market Forecast, 2020 – 2028

9.2.6.4. Compound Annual Growth Rate (CAGR)

9.2.6.5. Regional Bifurcation

9.2.6.5.1. North America

9.2.6.5.1.1. Market Estimation, 2015 – 2019

9.2.6.5.1.2. Market Forecast, 2020 – 2028

9.2.6.5.2. Europe

9.2.6.5.2.1. Market Estimation, 2015 – 2019

9.2.6.5.2.2. Market Forecast, 2020 – 2028

9.2.6.5.3. Asia Pacific

9.2.6.5.3.1. Market Estimation, 2015 – 2019

9.2.6.5.3.2. Market Forecast, 2020 – 2028

9.2.6.5.4. Middle East and Africa

9.2.6.5.4.1. Market Estimation, 2015 – 2019

9.2.6.5.4.2. Market Forecast, 2020 – 2028

9.2.6.5.5. Latin America

9.2.6.5.5.1. Market Estimation, 2015 – 2019

9.2.6.5.5.2. Market Forecast, 2020 – 2028

9.2.7. Duckweed LeafyBiomass

9.2.7.1. Definition

9.2.7.2. Market Estimation and Penetration, 2015 – 2019

9.2.7.3. Market Forecast, 2020 – 2028

9.2.7.4. Compound Annual Growth Rate (CAGR)

9.2.7.5. Regional Bifurcation

9.2.7.5.1. North America

9.2.7.5.1.1. Market Estimation, 2015 – 2019

9.2.7.5.1.2. Market Forecast, 2020 – 2028

9.2.7.5.2. Europe

9.2.7.5.2.1. Market Estimation, 2015 – 2019

9.2.7.5.2.2. Market Forecast, 2020 – 2028

9.2.7.5.3. Asia Pacific

9.2.7.5.3.1. Market Estimation, 2015 – 2019

9.2.7.5.3.2. Market Forecast, 2020 – 2028

9.2.7.5.4. Middle East and Africa

9.2.7.5.4.1. Market Estimation, 2015 – 2019

9.2.7.5.4.2. Market Forecast, 2020 – 2028

9.2.7.5.5. Latin America

9.2.7.5.5.1. Market Estimation, 2015 – 2019

9.2.7.5.5.2. Market Forecast, 2020 – 2028

9.2.8. Others

9.2.8.1. Definition

9.2.8.2. Market Estimation and Penetration, 2015 – 2019

9.2.8.3. Market Forecast, 2020 – 2028

9.2.8.4. Compound Annual Growth Rate (CAGR)

9.2.8.5. Regional Bifurcation

9.2.8.5.1. North America

9.2.8.5.1.1. Market Estimation, 2015 – 2019

9.2.8.5.1.2. Market Forecast, 2020 – 2028

9.2.8.5.2. Europe

9.2.8.5.2.1. Market Estimation, 2015 – 2019

9.2.8.5.2.2. Market Forecast, 2020 – 2028

9.2.8.5.3. Asia Pacific

9.2.8.5.3.1. Market Estimation, 2015 – 2019

9.2.8.5.3.2. Market Forecast, 2020 – 2028

9.2.8.5.4. Middle East and Africa

9.2.8.5.4.1. Market Estimation, 2015 – 2019

9.2.8.5.4.2. Market Forecast, 2020 – 2028

9.2.8.5.5. Latin America

9.2.8.5.5.1. Market Estimation, 2015 – 2019

9.2.8.5.5.2. Market Forecast, 2020 – 2028

9.3. Key Segment for Channeling Investments

9.3.1. By Source

10. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

10.1. Overview

10.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

10.2.1. Taliglucerase alfa

10.2.1.1. Definition

10.2.1.2. Market Estimation and Penetration, 2015 – 2019

10.2.1.3. Market Forecast, 2020 – 2028

10.2.1.4. Compound Annual Growth Rate (CAGR)

10.2.1.5. Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2015 – 2019

10.2.1.5.1.2. Market Forecast, 2020 – 2028

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2015 – 2019

10.2.1.5.2.2. Market Forecast, 2020 – 2028

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2015 – 2019

10.2.1.5.3.2. Market Forecast, 2020 – 2028

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2015 – 2019

10.2.1.5.4.2. Market Forecast, 2020 – 2028

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2015 – 2019

10.2.1.5.5.2. Market Forecast, 2020 – 2028

10.2.2. ZMApp

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2015 – 2019

10.2.2.3. Market Forecast, 2020 – 2028

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2015 – 2019

10.2.2.5.1.2. Market Forecast, 2020 – 2028

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2015 – 2019

10.2.2.5.2.2. Market Forecast, 2020 – 2028

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 – 2019

10.2.2.5.3.2. Market Forecast, 2020 – 2028

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 – 2019

10.2.2.5.4.2. Market Forecast, 2020 – 2028

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2015 – 2019

10.2.2.5.5.2. Market Forecast, 2020 – 2028

10.2.3. PRX-102

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2015 – 2019

10.2.3.3. Market Forecast, 2020 – 2028

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2015 – 2019

10.2.3.5.1.2. Market Forecast, 2020 – 2028

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2015 – 2019

10.2.3.5.2.2. Market Forecast, 2020 – 2028

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 – 2019

10.2.3.5.3.2. Market Forecast, 2020 – 2028

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 – 2019

10.2.3.5.4.2. Market Forecast, 2020 – 2028

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2015 – 2019

10.2.3.5.5.2. Market Forecast, 2020 – 2028

10.2.4. HAI-05

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2015 – 2019

10.2.4.3. Market Forecast, 2020 – 2028

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2015 – 2019

10.2.4.5.1.2. Market Forecast, 2020 – 2028

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2015 – 2019

10.2.4.5.2.2. Market Forecast, 2020 – 2028

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 – 2019

10.2.4.5.3.2. Market Forecast, 2020 – 2028

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 – 2019

10.2.4.5.4.2. Market Forecast, 2020 – 2028

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2015 – 2019

10.2.4.5.5.2. Market Forecast, 2020 – 2028

10.2.5. Others

10.2.5.1. Definition

10.2.5.2. Market Estimation and Penetration, 2015 – 2019

10.2.5.3. Market Forecast, 2020 – 2028

10.2.5.4. Compound Annual Growth Rate (CAGR)

10.2.5.5. Regional Bifurcation

10.2.5.5.1. North America

10.2.5.5.1.1. Market Estimation, 2015 – 2019

10.2.5.5.1.2. Market Forecast, 2020 – 2028

10.2.5.5.2. Europe

10.2.5.5.2.1. Market Estimation, 2015 – 2019

10.2.5.5.2.2. Market Forecast, 2020 – 2028

10.2.5.5.3. Asia Pacific

10.2.5.5.3.1. Market Estimation, 2015 – 2019

10.2.5.5.3.2. Market Forecast, 2020 – 2028

10.2.5.5.4. Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2015 – 2019

10.2.5.5.4.2. Market Forecast, 2020 – 2028

10.2.5.5.5. Latin America

10.2.5.5.5.1. Market Estimation, 2015 – 2019

10.2.5.5.5.2. Market Forecast, 2020 – 2028

10.3. Key Segment for Channeling Investments

10.3.1. By Product

11. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

11.1. Overview

11.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

11.2.1. HIV/AIDS

11.2.1.1. Definition

11.2.1.2. Market Estimation and Penetration, 2015 – 2019

11.2.1.3. Market Forecast, 2020 – 2028

11.2.1.4. Compound Annual Growth Rate (CAGR)

11.2.1.5. Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2015 – 2019

11.2.1.5.1.2. Market Forecast, 2020 – 2028

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2015 – 2019

11.2.1.5.2.2. Market Forecast, 2020 – 2028

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2015 – 2019

11.2.1.5.3.2. Market Forecast, 2020 – 2028

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2015 – 2019

11.2.1.5.4.2. Market Forecast, 2020 – 2028

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2015 – 2019

11.2.1.5.5.2. Market Forecast, 2020 – 2028

11.2.2. Ebola virus

11.2.2.1. Definition

11.2.2.2. Market Estimation and Penetration, 2015 – 2019

11.2.2.3. Market Forecast, 2020 – 2028

11.2.2.4. Compound Annual Growth Rate (CAGR)

11.2.2.5. Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2015 – 2019

11.2.2.5.1.2. Market Forecast, 2020 – 2028

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2015 – 2019

11.2.2.5.2.2. Market Forecast, 2020 – 2028

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2015 – 2019

11.2.2.5.3.2. Market Forecast, 2020 – 2028

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2015 – 2019

11.2.2.5.4.2. Market Forecast, 2020 – 2028

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2015 – 2019

11.2.2.5.5.2. Market Forecast, 2020 – 2028

11.2.3. Cholera

11.2.3.1. Definition

11.2.3.2. Market Estimation and Penetration, 2015 – 2019

11.2.3.3. Market Forecast, 2020 – 2028

11.2.3.4. Compound Annual Growth Rate (CAGR)

11.2.3.5. Regional Bifurcation

11.2.3.5.1. North America

11.2.3.5.1.1. Market Estimation, 2015 – 2019

11.2.3.5.1.2. Market Forecast, 2020 – 2028

11.2.3.5.2. Europe

11.2.3.5.2.1. Market Estimation, 2015 – 2019

11.2.3.5.2.2. Market Forecast, 2020 – 2028

11.2.3.5.3. Asia Pacific

11.2.3.5.3.1. Market Estimation, 2015 – 2019

11.2.3.5.3.2. Market Forecast, 2020 – 2028

11.2.3.5.4. Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2015 – 2019

11.2.3.5.4.2. Market Forecast, 2020 – 2028

11.2.3.5.5. Latin America

11.2.3.5.5.1. Market Estimation, 2015 – 2019

11.2.3.5.5.2. Market Forecast, 2020 – 2028

11.2.4. Leprosy

11.2.4.1. Definition

11.2.4.2. Market Estimation and Penetration, 2015 – 2019

11.2.4.3. Market Forecast, 2020 – 2028

11.2.4.4. Compound Annual Growth Rate (CAGR)

11.2.4.5. Regional Bifurcation

11.2.4.5.1. North America

11.2.4.5.1.1. Market Estimation, 2015 – 2019

11.2.4.5.1.2. Market Forecast, 2020 – 2028

11.2.4.5.2. Europe

11.2.4.5.2.1. Market Estimation, 2015 – 2019

11.2.4.5.2.2. Market Forecast, 2020 – 2028

11.2.4.5.3. Asia Pacific

11.2.4.5.3.1. Market Estimation, 2015 – 2019

11.2.4.5.3.2. Market Forecast, 2020 – 2028

11.2.4.5.4. Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2015 – 2019

11.2.4.5.4.2. Market Forecast, 2020 – 2028

11.2.4.5.5. Latin America

11.2.4.5.5.1. Market Estimation, 2015 – 2019

11.2.4.5.5.2. Market Forecast, 2020 – 2028

11.2.5. Tuberculosis

11.2.5.1. Definition

11.2.5.2. Market Estimation and Penetration, 2015 – 2019

11.2.5.3. Market Forecast, 2020 – 2028

11.2.5.4. Compound Annual Growth Rate (CAGR)

11.2.5.5. Regional Bifurcation

11.2.5.5.1. North America

11.2.5.5.1.1. Market Estimation, 2015 – 2019

11.2.5.5.1.2. Market Forecast, 2020 – 2028

11.2.5.5.2. Europe

11.2.5.5.2.1. Market Estimation, 2015 – 2019

11.2.5.5.2.2. Market Forecast, 2020 – 2028

11.2.5.5.3. Asia Pacific

11.2.5.5.3.1. Market Estimation, 2015 – 2019

11.2.5.5.3.2. Market Forecast, 2020 – 2028

11.2.5.5.4. Middle East and Africa

11.2.5.5.4.1. Market Estimation, 2015 – 2019

11.2.5.5.4.2. Market Forecast, 2020 – 2028

11.2.5.5.5. Latin America

11.2.5.5.5.1. Market Estimation, 2015 – 2019

11.2.5.5.5.2. Market Forecast, 2020 – 2028

11.2.6. Fabry Disease

11.2.6.1. Definition

11.2.6.2. Market Estimation and Penetration, 2015 – 2019

11.2.6.3. Market Forecast, 2020 – 2028

11.2.6.4. Compound Annual Growth Rate (CAGR)

11.2.6.5. Regional Bifurcation

11.2.6.5.1. North America

11.2.6.5.1.1. Market Estimation, 2015 – 2019

11.2.6.5.1.2. Market Forecast, 2020 – 2028

11.2.6.5.2. Europe

11.2.6.5.2.1. Market Estimation, 2015 – 2019

11.2.6.5.2.2. Market Forecast, 2020 – 2028

11.2.6.5.3. Asia Pacific

11.2.6.5.3.1. Market Estimation, 2015 – 2019

11.2.6.5.3.2. Market Forecast, 2020 – 2028

11.2.6.5.4. Middle East and Africa

11.2.6.5.4.1. Market Estimation, 2015 – 2019

11.2.6.5.4.2. Market Forecast, 2020 – 2028

11.2.6.5.5. Latin America

11.2.6.5.5.1. Market Estimation, 2015 – 2019

11.2.6.5.5.2. Market Forecast, 2020 – 2028

11.2.7. Anthrax

11.2.7.1. Definition

11.2.7.2. Market Estimation and Penetration, 2015 – 2019

11.2.7.3. Market Forecast, 2020 – 2028

11.2.7.4. Compound Annual Growth Rate (CAGR)

11.2.7.5. Regional Bifurcation

11.2.7.5.1. North America

11.2.7.5.1.1. Market Estimation, 2015 – 2019

11.2.7.5.1.2. Market Forecast, 2020 – 2028

11.2.7.5.2. Europe

11.2.7.5.2.1. Market Estimation, 2015 – 2019

11.2.7.5.2.2. Market Forecast, 2020 – 2028

11.2.7.5.3. Asia Pacific

11.2.7.5.3.1. Market Estimation, 2015 – 2019

11.2.7.5.3.2. Market Forecast, 2020 – 2028

11.2.7.5.4. Middle East and Africa

11.2.7.5.4.1. Market Estimation, 2015 – 2019

11.2.7.5.4.2. Market Forecast, 2020 – 2028

11.2.7.5.5. Latin America

11.2.7.5.5.1. Market Estimation, 2015 – 2019

11.2.7.5.5.2. Market Forecast, 2020 – 2028

11.2.8. Pompe Disease

11.2.8.1. Definition

11.2.8.2. Market Estimation and Penetration, 2015 – 2019

11.2.8.3. Market Forecast, 2020 – 2028

11.2.8.4. Compound Annual Growth Rate (CAGR)

11.2.8.5. Regional Bifurcation

11.2.8.5.1. North America

11.2.8.5.1.1. Market Estimation, 2015 – 2019

11.2.8.5.1.2. Market Forecast, 2020 – 2028

11.2.8.5.2. Europe

11.2.8.5.2.1. Market Estimation, 2015 – 2019

11.2.8.5.2.2. Market Forecast, 2020 – 2028

11.2.8.5.3. Asia Pacific

11.2.8.5.3.1. Market Estimation, 2015 – 2019

11.2.8.5.3.2. Market Forecast, 2020 – 2028

11.2.8.5.4. Middle East and Africa

11.2.8.5.4.1. Market Estimation, 2015 – 2019

11.2.8.5.4.2. Market Forecast, 2020 – 2028

11.2.8.5.5. Latin America

11.2.8.5.5.1. Market Estimation, 2015 – 2019

11.2.8.5.5.2. Market Forecast, 2020 – 2028

11.2.9. Influenza (Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation (2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Type A, Type B, Type C)

11.2.9.1. Type A

11.2.9.2. Type B

11.2.9.3. Type C

11.2.10. Alzheimer

11.2.10.1. Definition

11.2.10.2. Market Estimation and Penetration, 2015 – 2019

11.2.10.3. Market Forecast, 2020 – 2028

11.2.10.4. Compound Annual Growth Rate (CAGR)

11.2.10.5. Regional Bifurcation

11.2.10.5.1. North America

11.2.10.5.1.1. Market Estimation, 2015 – 2019

11.2.10.5.1.2. Market Forecast, 2020 – 2028

11.2.10.5.2. Europe

11.2.10.5.2.1. Market Estimation, 2015 – 2019

11.2.10.5.2.2. Market Forecast, 2020 – 2028

11.2.10.5.3. Asia Pacific

11.2.10.5.3.1. Market Estimation, 2015 – 2019

11.2.10.5.3.2. Market Forecast, 2020 – 2028

11.2.10.5.4. Middle East and Africa

11.2.10.5.4.1. Market Estimation, 2015 – 2019

11.2.10.5.4.2. Market Forecast, 2020 – 2028

11.2.10.5.5. Latin America

11.2.10.5.5.1. Market Estimation, 2015 – 2019

11.2.10.5.5.2. Market Forecast, 2020 – 2028

11.2.11. Respiratory Syndromes

11.2.11.1. Definition

11.2.11.2. Market Estimation and Penetration, 2015 – 2019

11.2.11.3. Market Forecast, 2020 – 2028

11.2.11.4. Compound Annual Growth Rate (CAGR)

11.2.11.5. Regional Bifurcation

11.2.11.5.1. North America

11.2.11.5.1.1. Market Estimation, 2015 – 2019

11.2.11.5.1.2. Market Forecast, 2020 – 2028

11.2.11.5.2. Europe

11.2.11.5.2.1. Market Estimation, 2015 – 2019

11.2.11.5.2.2. Market Forecast, 2020 – 2028

11.2.11.5.3. Asia Pacific

11.2.11.5.3.1. Market Estimation, 2015 – 2019

11.2.11.5.3.2. Market Forecast, 2020 – 2028

11.2.11.5.4. Middle East and Africa

11.2.11.5.4.1. Market Estimation, 2015 – 2019

11.2.11.5.4.2. Market Forecast, 2020 – 2028

11.2.11.5.5. Latin America

11.2.11.5.5.1. Market Estimation, 2015 – 2019

11.2.11.5.5.2. Market Forecast, 2020 – 2028

11.2.12. Gaucher disease

11.2.12.1. Definition

11.2.12.2. Market Estimation and Penetration, 2015 – 2019

11.2.12.3. Market Forecast, 2020 – 2028

11.2.12.4. Compound Annual Growth Rate (CAGR)

11.2.12.5. Regional Bifurcation

11.2.12.5.1. North America

11.2.12.5.1.1. Market Estimation, 2015 – 2019

11.2.12.5.1.2. Market Forecast, 2020 – 2028

11.2.12.5.2. Europe

11.2.12.5.2.1. Market Estimation, 2015 – 2019

11.2.12.5.2.2. Market Forecast, 2020 – 2028

11.2.12.5.3. Asia Pacific

11.2.12.5.3.1. Market Estimation, 2015 – 2019

11.2.12.5.3.2. Market Forecast, 2020 – 2028

11.2.12.5.4. Middle East and Africa

11.2.12.5.4.1. Market Estimation, 2015 – 2019

11.2.12.5.4.2. Market Forecast, 2020 – 2028

11.2.12.5.5. Latin America

11.2.12.5.5.1. Market Estimation, 2015 – 2019

11.2.12.5.5.2. Market Forecast, 2020 – 2028

11.2.13. Cancer

11.2.13.1. Definition

11.2.13.2. Market Estimation and Penetration, 2015 – 2019

11.2.13.3. Market Forecast, 2020 – 2028

11.2.13.4. Compound Annual Growth Rate (CAGR)

11.2.13.5. Regional Bifurcation

11.2.13.5.1. North America

11.2.13.5.1.1. Market Estimation, 2015 – 2019

11.2.13.5.1.2. Market Forecast, 2020 – 2028

11.2.13.5.2. Europe

11.2.13.5.2.1. Market Estimation, 2015 – 2019

11.2.13.5.2.2. Market Forecast, 2020 – 2028

11.2.13.5.3. Asia Pacific

11.2.13.5.3.1. Market Estimation, 2015 – 2019

11.2.13.5.3.2. Market Forecast, 2020 – 2028

11.2.13.5.4. Middle East and Africa

11.2.13.5.4.1. Market Estimation, 2015 – 2019

11.2.13.5.4.2. Market Forecast, 2020 – 2028

11.2.13.5.5. Latin America

11.2.13.5.5.1. Market Estimation, 2015 – 2019

11.2.13.5.5.2. Market Forecast, 2020 – 2028

11.2.14. Others

11.2.14.1. Definition

11.2.14.2. Market Estimation and Penetration, 2015 – 2019

11.2.14.3. Market Forecast, 2020 – 2028

11.2.14.4. Compound Annual Growth Rate (CAGR)

11.2.14.5. Regional Bifurcation

11.2.14.5.1. North America

11.2.14.5.1.1. Market Estimation, 2015 – 2019

11.2.14.5.1.2. Market Forecast, 2020 – 2028

11.2.14.5.2. Europe

11.2.14.5.2.1. Market Estimation, 2015 – 2019

11.2.14.5.2.2. Market Forecast, 2020 – 2028

11.2.14.5.3. Asia Pacific

11.2.14.5.3.1. Market Estimation, 2015 – 2019

11.2.14.5.3.2. Market Forecast, 2020 – 2028

11.2.14.5.4. Middle East and Africa

11.2.14.5.4.1. Market Estimation, 2015 – 2019

11.2.14.5.4.2. Market Forecast, 2020 – 2028

11.2.14.5.5. Latin America

11.2.14.5.5.1. Market Estimation, 2015 – 2019

11.2.14.5.5.2. Market Forecast, 2020 – 2028

11.3. Key Segment for Channeling Investments

11.3.1. By Diseases

12. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

12.1. Overview

12.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.2.1. Intramuscular

12.2.1.1. Definition

12.2.1.2. Market Estimation and Penetration, 2015 – 2019

12.2.1.3. Market Forecast, 2020 – 2028

12.2.1.4. Compound Annual Growth Rate (CAGR)

12.2.1.5. Regional Bifurcation

12.2.1.5.1. North America

12.2.1.5.1.1. Market Estimation, 2015 – 2019

12.2.1.5.1.2. Market Forecast, 2020 – 2028

12.2.1.5.2. Europe

12.2.1.5.2.1. Market Estimation, 2015 – 2019

12.2.1.5.2.2. Market Forecast, 2020 – 2028

12.2.1.5.3. Asia Pacific

12.2.1.5.3.1. Market Estimation, 2015 – 2019

12.2.1.5.3.2. Market Forecast, 2020 – 2028

12.2.1.5.4. Middle East and Africa

12.2.1.5.4.1. Market Estimation, 2015 – 2019

12.2.1.5.4.2. Market Forecast, 2020 – 2028

12.2.1.5.5. Latin America

12.2.1.5.5.1. Market Estimation, 2015 – 2019

12.2.1.5.5.2. Market Forecast, 2020 – 2028

12.2.2. Oral Administration

12.2.2.1. Definition

12.2.2.2. Market Estimation and Penetration, 2015 – 2019

12.2.2.3. Market Forecast, 2020 – 2028

12.2.2.4. Compound Annual Growth Rate (CAGR)

12.2.2.5. Regional Bifurcation

12.2.2.5.1. North America

12.2.2.5.1.1. Market Estimation, 2015 – 2019

12.2.2.5.1.2. Market Forecast, 2020 – 2028

12.2.2.5.2. Europe

12.2.2.5.2.1. Market Estimation, 2015 – 2019

12.2.2.5.2.2. Market Forecast, 2020 – 2028

12.2.2.5.3. Asia Pacific

12.2.2.5.3.1. Market Estimation, 2015 – 2019

12.2.2.5.3.2. Market Forecast, 2020 – 2028

12.2.2.5.4. Middle East and Africa

12.2.2.5.4.1. Market Estimation, 2015 – 2019

12.2.2.5.4.2. Market Forecast, 2020 – 2028

12.2.2.5.5. Latin America

12.2.2.5.5.1. Market Estimation, 2015 – 2019

12.2.2.5.5.2. Market Forecast, 2020 – 2028

12.2.3. Others

12.2.3.1. Definition

12.2.3.2. Market Estimation and Penetration, 2015 – 2019

12.2.3.3. Market Forecast, 2020 – 2028

12.2.3.4. Compound Annual Growth Rate (CAGR)

12.2.3.5. Regional Bifurcation

12.2.3.5.1. North America

12.2.3.5.1.1. Market Estimation, 2015 – 2019

12.2.3.5.1.2. Market Forecast, 2020 – 2028

12.2.3.5.2. Europe

12.2.3.5.2.1. Market Estimation, 2015 – 2019

12.2.3.5.2.2. Market Forecast, 2020 – 2028

12.2.3.5.3. Asia Pacific

12.2.3.5.3.1. Market Estimation, 2015 – 2019

12.2.3.5.3.2. Market Forecast, 2020 – 2028

12.2.3.5.4. Middle East and Africa

12.2.3.5.4.1. Market Estimation, 2015 – 2019

12.2.3.5.4.2. Market Forecast, 2020 – 2028

12.2.3.5.5. Latin America

12.2.3.5.5.1. Market Estimation, 2015 – 2019

12.2.3.5.5.2. Market Forecast, 2020 – 2028

12.3. Key Segment for Channeling Investments

12.3.1. By Mode of Administration

13. Global Plant-Based Biologics Market Analysis and Forecasts, 2020 – 2028

13.1. Overview

13.2. Global Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

13.2.1. Hospitals

13.2.1.1. Definition

13.2.1.2. Market Estimation and Penetration, 2015 – 2019

13.2.1.3. Market Forecast, 2020 – 2028

13.2.1.4. Compound Annual Growth Rate (CAGR)

13.2.1.5. Regional Bifurcation

13.2.1.5.1. North America

13.2.1.5.1.1. Market Estimation, 2015 – 2019

13.2.1.5.1.2. Market Forecast, 2020 – 2028

13.2.1.5.2. Europe

13.2.1.5.2.1. Market Estimation, 2015 – 2019

13.2.1.5.2.2. Market Forecast, 2020 – 2028

13.2.1.5.3. Asia Pacific

13.2.1.5.3.1. Market Estimation, 2015 – 2019

13.2.1.5.3.2. Market Forecast, 2020 – 2028

13.2.1.5.4. Middle East and Africa

13.2.1.5.4.1. Market Estimation, 2015 – 2019

13.2.1.5.4.2. Market Forecast, 2020 – 2028

13.2.1.5.5. Latin America

13.2.1.5.5.1. Market Estimation, 2015 – 2019

13.2.1.5.5.2. Market Forecast, 2020 – 2028

13.2.2. Clinics

13.2.2.1. Definition

13.2.2.2. Market Estimation and Penetration, 2015 – 2019

13.2.2.3. Market Forecast, 2020 – 2028

13.2.2.4. Compound Annual Growth Rate (CAGR)

13.2.2.5. Regional Bifurcation

13.2.2.5.1. North America

13.2.2.5.1.1. Market Estimation, 2015 – 2019

13.2.2.5.1.2. Market Forecast, 2020 – 2028

13.2.2.5.2. Europe

13.2.2.5.2.1. Market Estimation, 2015 – 2019

13.2.2.5.2.2. Market Forecast, 2020 – 2028

13.2.2.5.3. Asia Pacific

13.2.2.5.3.1. Market Estimation, 2015 – 2019

13.2.2.5.3.2. Market Forecast, 2020 – 2028

13.2.2.5.4. Middle East and Africa

13.2.2.5.4.1. Market Estimation, 2015 – 2019

13.2.2.5.4.2. Market Forecast, 2020 – 2028

13.2.2.5.5. Latin America

13.2.2.5.5.1. Market Estimation, 2015 – 2019

13.2.2.5.5.2. Market Forecast, 2020 – 2028

13.2.3. Primary Care Centers

13.2.3.1. Definition

13.2.3.2. Market Estimation and Penetration, 2015 – 2019

13.2.3.3. Market Forecast, 2020 – 2028

13.2.3.4. Compound Annual Growth Rate (CAGR)

13.2.3.5. Regional Bifurcation

13.2.3.5.1. North America

13.2.3.5.1.1. Market Estimation, 2015 – 2019

13.2.3.5.1.2. Market Forecast, 2020 – 2028

13.2.3.5.2. Europe

13.2.3.5.2.1. Market Estimation, 2015 – 2019

13.2.3.5.2.2. Market Forecast, 2020 – 2028

13.2.3.5.3. Asia Pacific

13.2.3.5.3.1. Market Estimation, 2015 – 2019

13.2.3.5.3.2. Market Forecast, 2020 – 2028

13.2.3.5.4. Middle East and Africa

13.2.3.5.4.1. Market Estimation, 2015 – 2019

13.2.3.5.4.2. Market Forecast, 2020 – 2028

13.2.3.5.5. Latin America

13.2.3.5.5.1. Market Estimation, 2015 – 2019

13.2.3.5.5.2. Market Forecast, 2020 – 2028

13.2.4. Others

13.2.4.1. Definition

13.2.4.2. Market Estimation and Penetration, 2015 – 2019

13.2.4.3. Market Forecast, 2020 – 2028

13.2.4.4. Compound Annual Growth Rate (CAGR)

13.2.4.5. Regional Bifurcation

13.2.4.5.1. North America

13.2.4.5.1.1. Market Estimation, 2015 – 2019

13.2.4.5.1.2. Market Forecast, 2020 – 2028

13.2.4.5.2. Europe

13.2.4.5.2.1. Market Estimation, 2015 – 2019

13.2.4.5.2.2. Market Forecast, 2020 – 2028

13.2.4.5.3. Asia Pacific

13.2.4.5.3.1. Market Estimation, 2015 – 2019

13.2.4.5.3.2. Market Forecast, 2020 – 2028

13.2.4.5.4. Middle East and Africa

13.2.4.5.4.1. Market Estimation, 2015 – 2019

13.2.4.5.4.2. Market Forecast, 2020 – 2028

13.2.4.5.5. Latin America

13.2.4.5.5.1. Market Estimation, 2015 – 2019

13.2.4.5.5.2. Market Forecast, 2020 – 2028

13.3. Key Segment for Channeling Investments

13.3.1. By End Users

14. North America Plant-Based Biologics Market Analysis and Forecasts, 2020 - 2028

14.1. Overview

14.1.1. North America Plant-Based Biologics Market Revenue (US$ Mn)

14.2. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

14.2.1. Phase I

14.2.2. Phase II

14.2.3. Others

14.3. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

14.3.1. Tobacco, tobacco cells, tobacco leaves

14.3.2. Nicotiana benthamiana leaves

14.3.3. Carrot cell culture

14.3.4. Rice seeds

14.3.5. Moss

14.3.6. Algae

14.3.7. Duckweed LeafyBiomass

14.3.8. Others

14.4. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

14.4.1. Taliglucerase alfa

14.4.2. ZMApp

14.4.3. PRX-102

14.4.4. HAI-05

14.4.5. Others

14.5. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

14.5.1. HIV/AIDS

14.5.2. Ebola virus

14.5.3. Cholera

14.5.4. Leprosy

14.5.5. Tuberculosis

14.5.6. Fabry Disease

14.5.7. Anthrax

14.5.8. Pompe Disease

14.5.9. Influenza

14.5.9.1. Type A

14.5.9.2. Type B

14.5.9.3. Type C

14.5.10. Alzheimer

14.5.11. Respiratory Syndromes

14.5.12. Gaucher disease

14.5.13. Cancer

14.5.14. Others

14.6. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.1. Intramuscular

14.6.2. Oral Administration

14.6.3. Others

14.7. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.1. Hospitals

14.7.2. Clinics

14.7.3. Primary Care Centers

14.7.4. Others

14.8. North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

14.8.1. U.S

14.8.1.1. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

14.8.1.1.1. Phase I

14.8.1.1.2. Phase II

14.8.1.1.3. Others

14.8.1.2. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

14.8.1.2.1. Tobacco, tobacco cells, tobacco leaves

14.8.1.2.2. Nicotiana benthamiana leaves

14.8.1.2.3. Carrot cell culture

14.8.1.2.4. Rice seeds

14.8.1.2.5. Moss

14.8.1.2.6. Algae

14.8.1.2.7. Duckweed LeafyBiomass

14.8.1.2.8. Others

14.8.1.3. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

14.8.1.3.1. Taliglucerase alfa

14.8.1.3.2. ZMApp

14.8.1.3.3. PRX-102

14.8.1.3.4. HAI-05

14.8.1.3.5. Others

14.8.1.4. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

14.8.1.4.1. HIV/AIDS

14.8.1.4.2. Ebola virus

14.8.1.4.3. Cholera

14.8.1.4.4. Leprosy

14.8.1.4.5. Tuberculosis

14.8.1.4.6. Fabry Disease

14.8.1.4.7. Anthrax

14.8.1.4.8. Pompe Disease

14.8.1.4.9. Influenza

14.8.1.4.9.1. Type A

14.8.1.4.9.2. Type B

14.8.1.4.9.3. Type C

14.8.1.4.10. Alzheimer

14.8.1.4.11. Respiratory Syndromes

14.8.1.4.12. Gaucher disease

14.8.1.4.13. Cancer

14.8.1.4.14. Others

14.8.1.5. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.8.1.5.1. Intramuscular

14.8.1.5.2. Oral Administration

14.8.1.5.3. Others

14.8.1.6. U.S Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.1.6.1. Hospitals

14.8.1.6.2. Clinics

14.8.1.6.3. Primary Care Centers

14.8.1.6.4. Others

14.8.2. Canada

14.8.2.1. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

14.8.2.1.1. Phase I

14.8.2.1.2. Phase II

14.8.2.1.3. Others

14.8.2.2. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

14.8.2.2.1. Tobacco, tobacco cells, tobacco leaves

14.8.2.2.2. Nicotiana benthamiana leaves

14.8.2.2.3. Carrot cell culture

14.8.2.2.4. Rice seeds

14.8.2.2.5. Moss

14.8.2.2.6. Algae

14.8.2.2.7. Duckweed LeafyBiomass

14.8.2.2.8. Others

14.8.2.3. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

14.8.2.3.1. Taliglucerase alfa

14.8.2.3.2. ZMApp

14.8.2.3.3. PRX-102

14.8.2.3.4. HAI-05

14.8.2.3.5. Others

14.8.2.4. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

14.8.2.4.1. HIV/AIDS

14.8.2.4.2. Ebola virus

14.8.2.4.3. Cholera

14.8.2.4.4. Leprosy

14.8.2.4.5. Tuberculosis

14.8.2.4.6. Fabry Disease

14.8.2.4.7. Anthrax

14.8.2.4.8. Pompe Disease

14.8.2.4.9. Influenza

14.8.2.4.9.1. Type A

14.8.2.4.9.2. Type B

14.8.2.4.9.3. Type C

14.8.2.4.10. Alzheimer

14.8.2.4.11. Respiratory Syndromes

14.8.2.4.12. Gaucher disease

14.8.2.4.13. Cancer

14.8.2.4.14. Others

14.8.2.5. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.8.2.5.1. Intramuscular

14.8.2.5.2. Oral Administration

14.8.2.5.3. Others

14.8.2.6. Canada Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.2.6.1. Hospitals

14.8.2.6.2. Clinics

14.8.2.6.3. Primary Care Centers

14.8.2.6.4. Others

14.8.3. Mexico

14.8.3.1. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

14.8.3.1.1. Phase I

14.8.3.1.2. Phase II

14.8.3.1.3. Others

14.8.3.2. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

14.8.3.2.1. Tobacco, tobacco cells, tobacco leaves

14.8.3.2.2. Nicotiana benthamiana leaves

14.8.3.2.3. Carrot cell culture

14.8.3.2.4. Rice seeds

14.8.3.2.5. Moss

14.8.3.2.6. Algae

14.8.3.2.7. Duckweed LeafyBiomass

14.8.3.2.8. Others

14.8.3.3. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

14.8.3.3.1. Taliglucerase alfa

14.8.3.3.2. ZMApp

14.8.3.3.3. PRX-102

14.8.3.3.4. HAI-05

14.8.3.3.5. Others

14.8.3.4. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

14.8.3.4.1. HIV/AIDS

14.8.3.4.2. Ebola virus

14.8.3.4.3. Cholera

14.8.3.4.4. Leprosy

14.8.3.4.5. Tuberculosis

14.8.3.4.6. Fabry Disease

14.8.3.4.7. Anthrax

14.8.3.4.8. Pompe Disease

14.8.3.4.9. Influenza

14.8.3.4.9.1. Type A

14.8.3.4.9.2. Type B

14.8.3.4.9.3. Type C

14.8.3.4.10. Alzheimer

14.8.3.4.11. Respiratory Syndromes

14.8.3.4.12. Gaucher disease

14.8.3.4.13. Cancer

14.8.3.4.14. Others

14.8.3.5. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.8.3.5.1. Intramuscular

14.8.3.5.2. Oral Administration

14.8.3.5.3. Others

14.8.3.6. Mexico Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.3.6.1. Hospitals

14.8.3.6.2. Clinics

14.8.3.6.3. Primary Care Centers

14.8.3.6.4. Others

14.8.4. Rest of North America

14.8.4.1. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

14.8.4.1.1. Phase I

14.8.4.1.2. Phase II

14.8.4.1.3. Others

14.8.4.2. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

14.8.4.2.1. Tobacco, tobacco cells, tobacco leaves

14.8.4.2.2. Nicotiana benthamiana leaves

14.8.4.2.3. Carrot cell culture

14.8.4.2.4. Rice seeds

14.8.4.2.5. Moss

14.8.4.2.6. Algae

14.8.4.2.7. Duckweed LeafyBiomass

14.8.4.2.8. Others

14.8.4.3. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

14.8.4.3.1. Taliglucerase alfa

14.8.4.3.2. ZMApp

14.8.4.3.3. PRX-102

14.8.4.3.4. HAI-05

14.8.4.3.5. Others

14.8.4.4. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

14.8.4.4.1. HIV/AIDS

14.8.4.4.2. Ebola virus

14.8.4.4.3. Cholera

14.8.4.4.4. Leprosy

14.8.4.4.5. Tuberculosis

14.8.4.4.6. Fabry Disease

14.8.4.4.7. Anthrax

14.8.4.4.8. Pompe Disease

14.8.4.4.9. Influenza

14.8.4.4.9.1. Type A

14.8.4.4.9.2. Type B

14.8.4.4.9.3. Type C

14.8.4.4.10. Alzheimer

14.8.4.4.11. Respiratory Syndromes

14.8.4.4.12. Gaucher disease

14.8.4.4.13. Cancer

14.8.4.4.14. Others

14.8.4.5. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.8.4.5.1. Intramuscular

14.8.4.5.2. Oral Administration

14.8.4.5.3. Others

14.8.4.6. Rest of North America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.4.6.1. Hospitals

14.8.4.6.2. Clinics

14.8.4.6.3. Primary Care Centers

14.8.4.6.4. Others

14.9. Key Segment for Channeling Investments

14.9.1. By Country

14.9.2. By Clinical Trail

14.9.3. By Source

14.9.4. By Product

14.9.5. By Diseases

14.9.6. By Mode of Administration

14.9.7. By End Users

15. Europe Plant-Based Biologics Market Analysis and Forecasts, 2020 - 2028

15.1. Overview

15.1.1. Europe Plant-Based Biologics Market Revenue (US$ Mn)

15.2. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.2.1. Phase I

15.2.2. Phase II

15.2.3. Others

15.3. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.3.1. Tobacco, tobacco cells, tobacco leaves

15.3.2. Nicotiana benthamiana leaves

15.3.3. Carrot cell culture

15.3.4. Rice seeds

15.3.5. Moss

15.3.6. Algae

15.3.7. Duckweed LeafyBiomass

15.3.8. Others

15.4. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.4.1. Taliglucerase alfa

15.4.2. ZMApp

15.4.3. PRX-102

15.4.4. HAI-05

15.4.5. Others

15.5. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.5.1. HIV/AIDS

15.5.2. Ebola virus

15.5.3. Cholera

15.5.4. Leprosy

15.5.5. Tuberculosis

15.5.6. Fabry Disease

15.5.7. Anthrax

15.5.8. Pompe Disease

15.5.9. Influenza

15.5.9.1. Type A

15.5.9.2. Type B

15.5.9.3. Type C

15.5.10. Alzheimer

15.5.11. Respiratory Syndromes

15.5.12. Gaucher disease

15.5.13. Cancer

15.5.14. Others

15.6. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.1. Intramuscular

15.6.2. Oral Administration

15.6.3. Others

15.7. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.1. Hospitals

15.7.2. Clinics

15.7.3. Primary Care Centers

15.7.4. Others

15.8. Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

15.8.1. France

15.8.1.1. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.1.1.1. Phase I

15.8.1.1.2. Phase II

15.8.1.1.3. Others

15.8.1.2. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.1.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.1.2.2. Nicotiana benthamiana leaves

15.8.1.2.3. Carrot cell culture

15.8.1.2.4. Rice seeds

15.8.1.2.5. Moss

15.8.1.2.6. Algae

15.8.1.2.7. Duckweed LeafyBiomass

15.8.1.2.8. Others

15.8.1.3. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.1.3.1. Taliglucerase alfa

15.8.1.3.2. ZMApp

15.8.1.3.3. PRX-102

15.8.1.3.4. HAI-05

15.8.1.3.5. Others

15.8.1.4. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.1.4.1. HIV/AIDS

15.8.1.4.2. Ebola virus

15.8.1.4.3. Cholera

15.8.1.4.4. Leprosy

15.8.1.4.5. Tuberculosis

15.8.1.4.6. Fabry Disease

15.8.1.4.7. Anthrax

15.8.1.4.8. Pompe Disease

15.8.1.4.9. Influenza

15.8.1.4.9.1. Type A

15.8.1.4.9.2. Type B

15.8.1.4.9.3. Type C

15.8.1.4.10. Alzheimer

15.8.1.4.11. Respiratory Syndromes

15.8.1.4.12. Gaucher disease

15.8.1.4.13. Cancer

15.8.1.4.14. Others

15.8.1.5. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.1.5.1. Intramuscular

15.8.1.5.2. Oral Administration

15.8.1.5.3. Others

15.8.1.6. France Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.1.6.1. Hospitals

15.8.1.6.2. Clinics

15.8.1.6.3. Primary Care Centers

15.8.1.6.4. Others

15.8.2. The UK

15.8.2.1. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.2.1.1. Phase I

15.8.2.1.2. Phase II

15.8.2.1.3. Others

15.8.2.2. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.2.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.2.2.2. Nicotiana benthamiana leaves

15.8.2.2.3. Carrot cell culture

15.8.2.2.4. Rice seeds

15.8.2.2.5. Moss

15.8.2.2.6. Algae

15.8.2.2.7. Duckweed LeafyBiomass

15.8.2.2.8. Others

15.8.2.3. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.2.3.1. Taliglucerase alfa

15.8.2.3.2. ZMApp

15.8.2.3.3. PRX-102

15.8.2.3.4. HAI-05

15.8.2.3.5. Others

15.8.2.4. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.2.4.1. HIV/AIDS

15.8.2.4.2. Ebola virus

15.8.2.4.3. Cholera

15.8.2.4.4. Leprosy

15.8.2.4.5. Tuberculosis

15.8.2.4.6. Fabry Disease

15.8.2.4.7. Anthrax

15.8.2.4.8. Pompe Disease

15.8.2.4.9. Influenza

15.8.2.4.9.1. Type A

15.8.2.4.9.2. Type B

15.8.2.4.9.3. Type C

15.8.2.4.10. Alzheimer

15.8.2.4.11. Respiratory Syndromes

15.8.2.4.12. Gaucher disease

15.8.2.4.13. Cancer

15.8.2.4.14. Others

15.8.2.5. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.2.5.1. Intramuscular

15.8.2.5.2. Oral Administration

15.8.2.5.3. Others

15.8.2.6. The UK Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.2.6.1. Hospitals

15.8.2.6.2. Clinics

15.8.2.6.3. Primary Care Centers

15.8.2.6.4. Others

15.8.3. Spain

15.8.3.1. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.3.1.1. Phase I

15.8.3.1.2. Phase II

15.8.3.1.3. Others

15.8.3.2. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.3.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.3.2.2. Nicotiana benthamiana leaves

15.8.3.2.3. Carrot cell culture

15.8.3.2.4. Rice seeds

15.8.3.2.5. Moss

15.8.3.2.6. Algae

15.8.3.2.7. Duckweed LeafyBiomass

15.8.3.2.8. Others

15.8.3.3. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.3.3.1. Taliglucerase alfa

15.8.3.3.2. ZMApp

15.8.3.3.3. PRX-102

15.8.3.3.4. HAI-05

15.8.3.3.5. Others

15.8.3.4. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.3.4.1. HIV/AIDS

15.8.3.4.2. Ebola virus

15.8.3.4.3. Cholera

15.8.3.4.4. Leprosy

15.8.3.4.5. Tuberculosis

15.8.3.4.6. Fabry Disease

15.8.3.4.7. Anthrax

15.8.3.4.8. Pompe Disease

15.8.3.4.9. Influenza

15.8.3.4.9.1. Type A

15.8.3.4.9.2. Type B

15.8.3.4.9.3. Type C

15.8.3.4.10. Alzheimer

15.8.3.4.11. Respiratory Syndromes

15.8.3.4.12. Gaucher disease

15.8.3.4.13. Cancer

15.8.3.4.14. Others

15.8.3.5. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.3.5.1. Intramuscular

15.8.3.5.2. Oral Administration

15.8.3.5.3. Others

15.8.3.6. Spain Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.3.6.1. Hospitals

15.8.3.6.2. Clinics

15.8.3.6.3. Primary Care Centers

15.8.3.6.4. Others

15.8.4. Germany

15.8.4.1. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.4.1.1. Phase I

15.8.4.1.2. Phase II

15.8.4.1.3. Others

15.8.4.2. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.4.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.4.2.2. Nicotiana benthamiana leaves

15.8.4.2.3. Carrot cell culture

15.8.4.2.4. Rice seeds

15.8.4.2.5. Moss

15.8.4.2.6. Algae

15.8.4.2.7. Duckweed LeafyBiomass

15.8.4.2.8. Others

15.8.4.3. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.4.3.1. Taliglucerase alfa

15.8.4.3.2. ZMApp

15.8.4.3.3. PRX-102

15.8.4.3.4. HAI-05

15.8.4.3.5. Others

15.8.4.4. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.4.4.1. HIV/AIDS

15.8.4.4.2. Ebola virus

15.8.4.4.3. Cholera

15.8.4.4.4. Leprosy

15.8.4.4.5. Tuberculosis

15.8.4.4.6. Fabry Disease

15.8.4.4.7. Anthrax

15.8.4.4.8. Pompe Disease

15.8.4.4.9. Influenza

15.8.4.4.9.1. Type A

15.8.4.4.9.2. Type B

15.8.4.4.9.3. Type C

15.8.4.4.10. Alzheimer

15.8.4.4.11. Respiratory Syndromes

15.8.4.4.12. Gaucher disease

15.8.4.4.13. Cancer

15.8.4.4.14. Others

15.8.4.5. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.4.5.1. Intramuscular

15.8.4.5.2. Oral Administration

15.8.4.5.3. Others

15.8.4.6. Germany Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.4.6.1. Hospitals

15.8.4.6.2. Clinics

15.8.4.6.3. Primary Care Centers

15.8.4.6.4. Others

15.8.5. Italy

15.8.5.1. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.5.1.1. Phase I

15.8.5.1.2. Phase II

15.8.5.1.3. Others

15.8.5.2. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.5.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.5.2.2. Nicotiana benthamiana leaves

15.8.5.2.3. Carrot cell culture

15.8.5.2.4. Rice seeds

15.8.5.2.5. Moss

15.8.5.2.6. Algae

15.8.5.2.7. Duckweed LeafyBiomass

15.8.5.2.8. Others

15.8.5.3. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.5.3.1. Taliglucerase alfa

15.8.5.3.2. ZMApp

15.8.5.3.3. PRX-102

15.8.5.3.4. HAI-05

15.8.5.3.5. Others

15.8.5.4. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.5.4.1. HIV/AIDS

15.8.5.4.2. Ebola virus

15.8.5.4.3. Cholera

15.8.5.4.4. Leprosy

15.8.5.4.5. Tuberculosis

15.8.5.4.6. Fabry Disease

15.8.5.4.7. Anthrax

15.8.5.4.8. Pompe Disease

15.8.5.4.9. Influenza

15.8.5.4.9.1. Type A

15.8.5.4.9.2. Type B

15.8.5.4.9.3. Type C

15.8.5.4.10. Alzheimer

15.8.5.4.11. Respiratory Syndromes

15.8.5.4.12. Gaucher disease

15.8.5.4.13. Cancer

15.8.5.4.14. Others

15.8.5.5. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.5.5.1. Intramuscular

15.8.5.5.2. Oral Administration

15.8.5.5.3. Others

15.8.5.6. Italy Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.5.6.1. Hospitals

15.8.5.6.2. Clinics

15.8.5.6.3. Primary Care Centers

15.8.5.6.4. Others

15.8.6. Nordic Countries

15.8.6.1. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.6.1.1. Phase I

15.8.6.1.2. Phase II

15.8.6.1.3. Others

15.8.6.2. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.6.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.6.2.2. Nicotiana benthamiana leaves

15.8.6.2.3. Carrot cell culture

15.8.6.2.4. Rice seeds

15.8.6.2.5. Moss

15.8.6.2.6. Algae

15.8.6.2.7. Duckweed LeafyBiomass

15.8.6.2.8. Others

15.8.6.3. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.6.3.1. Taliglucerase alfa

15.8.6.3.2. ZMApp

15.8.6.3.3. PRX-102

15.8.6.3.4. HAI-05

15.8.6.3.5. Others

15.8.6.4. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.6.4.1. HIV/AIDS

15.8.6.4.2. Ebola virus

15.8.6.4.3. Cholera

15.8.6.4.4. Leprosy

15.8.6.4.5. Tuberculosis

15.8.6.4.6. Fabry Disease

15.8.6.4.7. Anthrax

15.8.6.4.8. Pompe Disease

15.8.6.4.9. Influenza

15.8.6.4.9.1. Type A

15.8.6.4.9.2. Type B

15.8.6.4.9.3. Type C

15.8.6.4.10. Alzheimer

15.8.6.4.11. Respiratory Syndromes

15.8.6.4.12. Gaucher disease

15.8.6.4.13. Cancer

15.8.6.4.14. Others

15.8.6.5. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.6.5.1. Intramuscular

15.8.6.5.2. Oral Administration

15.8.6.5.3. Others

15.8.6.6. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.6.6.1. Hospitals

15.8.6.6.2. Clinics

15.8.6.6.3. Primary Care Centers

15.8.6.6.4. Others

15.8.6.7. Nordic Countries Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

15.8.6.7.1. Denmark

15.8.6.7.2. Finland

15.8.6.7.3. Iceland

15.8.6.7.4. Sweden

15.8.6.7.5. Norway

15.8.7. Benelux Union

15.8.7.1. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.7.1.1. Phase I

15.8.7.1.2. Phase II

15.8.7.1.3. Others

15.8.7.2. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.7.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.7.2.2. Nicotiana benthamiana leaves

15.8.7.2.3. Carrot cell culture

15.8.7.2.4. Rice seeds

15.8.7.2.5. Moss

15.8.7.2.6. Algae

15.8.7.2.7. Duckweed LeafyBiomass

15.8.7.2.8. Others

15.8.7.3. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.7.3.1. Taliglucerase alfa

15.8.7.3.2. ZMApp

15.8.7.3.3. PRX-102

15.8.7.3.4. HAI-05

15.8.7.3.5. Others

15.8.7.4. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.7.4.1. HIV/AIDS

15.8.7.4.2. Ebola virus

15.8.7.4.3. Cholera

15.8.7.4.4. Leprosy

15.8.7.4.5. Tuberculosis

15.8.7.4.6. Fabry Disease

15.8.7.4.7. Anthrax

15.8.7.4.8. Pompe Disease

15.8.7.4.9. Influenza

15.8.7.4.9.1. Type A

15.8.7.4.9.2. Type B

15.8.7.4.9.3. Type C

15.8.7.4.10. Alzheimer

15.8.7.4.11. Respiratory Syndromes

15.8.7.4.12. Gaucher disease

15.8.7.4.13. Cancer

15.8.7.4.14. Others

15.8.7.5. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.7.5.1. Intramuscular

15.8.7.5.2. Oral Administration

15.8.7.5.3. Others

15.8.7.6. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.7.6.1. Hospitals

15.8.7.6.2. Clinics

15.8.7.6.3. Primary Care Centers

15.8.7.6.4. Others

15.8.7.7. Benelux Union Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

15.8.7.7.1. Belgium

15.8.7.7.2. The Netherlands

15.8.7.7.3. Luxembourg

15.8.8. Rest of Europe

15.8.8.1. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

15.8.8.1.1. Phase I

15.8.8.1.2. Phase II

15.8.8.1.3. Others

15.8.8.2. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

15.8.8.2.1. Tobacco, tobacco cells, tobacco leaves

15.8.8.2.2. Nicotiana benthamiana leaves

15.8.8.2.3. Carrot cell culture

15.8.8.2.4. Rice seeds

15.8.8.2.5. Moss

15.8.8.2.6. Algae

15.8.8.2.7. Duckweed LeafyBiomass

15.8.8.2.8. Others

15.8.8.3. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

15.8.8.3.1. Taliglucerase alfa

15.8.8.3.2. ZMApp

15.8.8.3.3. PRX-102

15.8.8.3.4. HAI-05

15.8.8.3.5. Others

15.8.8.4. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

15.8.8.4.1. HIV/AIDS

15.8.8.4.2. Ebola virus

15.8.8.4.3. Cholera

15.8.8.4.4. Leprosy

15.8.8.4.5. Tuberculosis

15.8.8.4.6. Fabry Disease

15.8.8.4.7. Anthrax

15.8.8.4.8. Pompe Disease

15.8.8.4.9. Influenza

15.8.8.4.9.1. Type A

15.8.8.4.9.2. Type B

15.8.8.4.9.3. Type C

15.8.8.4.10. Alzheimer

15.8.8.4.11. Respiratory Syndromes

15.8.8.4.12. Gaucher disease

15.8.8.4.13. Cancer

15.8.8.4.14. Others

15.8.8.5. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.8.8.5.1. Intramuscular

15.8.8.5.2. Oral Administration

15.8.8.5.3. Others

15.8.8.6. Rest of Europe Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.8.6.1. Hospitals

15.8.8.6.2. Clinics

15.8.8.6.3. Primary Care Centers

15.8.8.6.4. Others

15.9. Key Segment for Channeling Investments

15.9.1. By Country

15.9.2. By Clinical Trail

15.9.3. By Source

15.9.4. By Product

15.9.5. By Diseases

15.9.6. By Mode of Administration

15.9.7. By End Users

16. Asia Pacific Plant-Based Biologics Market Analysis and Forecasts, 2020 - 2028

16.1. Overview

16.1.1. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn)

16.2. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.2.1. Phase I

16.2.2. Phase II

16.2.3. Others

16.3. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.3.1. Tobacco, tobacco cells, tobacco leaves

16.3.2. Nicotiana benthamiana leaves

16.3.3. Carrot cell culture

16.3.4. Rice seeds

16.3.5. Moss

16.3.6. Algae

16.3.7. Duckweed LeafyBiomass

16.3.8. Others

16.4. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.4.1. Taliglucerase alfa

16.4.2. ZMApp

16.4.3. PRX-102

16.4.4. HAI-05

16.4.5. Others

16.5. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.5.1. HIV/AIDS

16.5.2. Ebola virus

16.5.3. Cholera

16.5.4. Leprosy

16.5.5. Tuberculosis

16.5.6. Fabry Disease

16.5.7. Anthrax

16.5.8. Pompe Disease

16.5.9. Influenza

16.5.9.1. Type A

16.5.9.2. Type B

16.5.9.3. Type C

16.5.10. Alzheimer

16.5.11. Respiratory Syndromes

16.5.12. Gaucher disease

16.5.13. Cancer

16.5.14. Others

16.6. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.6.1. Intramuscular

16.6.2. Oral Administration

16.6.3. Others

16.7. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.1. Hospitals

16.7.2. Clinics

16.7.3. Primary Care Centers

16.7.4. Others

16.8. Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

16.8.1. China

16.8.1.1. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.1.1.1. Phase I

16.8.1.1.2. Phase II

16.8.1.1.3. Others

16.8.1.2. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.1.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.1.2.2. Nicotiana benthamiana leaves

16.8.1.2.3. Carrot cell culture

16.8.1.2.4. Rice seeds

16.8.1.2.5. Moss

16.8.1.2.6. Algae

16.8.1.2.7. Duckweed LeafyBiomass

16.8.1.2.8. Others

16.8.1.3. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.1.3.1. Taliglucerase alfa

16.8.1.3.2. ZMApp

16.8.1.3.3. PRX-102

16.8.1.3.4. HAI-05

16.8.1.3.5. Others

16.8.1.4. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.1.4.1. HIV/AIDS

16.8.1.4.2. Ebola virus

16.8.1.4.3. Cholera

16.8.1.4.4. Leprosy

16.8.1.4.5. Tuberculosis

16.8.1.4.6. Fabry Disease

16.8.1.4.7. Anthrax

16.8.1.4.8. Pompe Disease

16.8.1.4.9. Influenza

16.8.1.4.9.1. Type A

16.8.1.4.9.2. Type B

16.8.1.4.9.3. Type C

16.8.1.4.10. Alzheimer

16.8.1.4.11. Respiratory Syndromes

16.8.1.4.12. Gaucher disease

16.8.1.4.13. Cancer

16.8.1.4.14. Others

16.8.1.5. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.1.5.1. Intramuscular

16.8.1.5.2. Oral Administration

16.8.1.5.3. Others

16.8.1.6. China Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.1.6.1. Hospitals

16.8.1.6.2. Clinics

16.8.1.6.3. Primary Care Centers

16.8.1.6.4. Others

16.8.2. Japan

16.8.2.1. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.2.1.1. Phase I

16.8.2.1.2. Phase II

16.8.2.1.3. Others

16.8.2.2. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.2.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.2.2.2. Nicotiana benthamiana leaves

16.8.2.2.3. Carrot cell culture

16.8.2.2.4. Rice seeds

16.8.2.2.5. Moss

16.8.2.2.6. Algae

16.8.2.2.7. Duckweed LeafyBiomass

16.8.2.2.8. Others

16.8.2.3. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.2.3.1. Taliglucerase alfa

16.8.2.3.2. ZMApp

16.8.2.3.3. PRX-102

16.8.2.3.4. HAI-05

16.8.2.3.5. Others

16.8.2.4. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.2.4.1. HIV/AIDS

16.8.2.4.2. Ebola virus

16.8.2.4.3. Cholera

16.8.2.4.4. Leprosy

16.8.2.4.5. Tuberculosis

16.8.2.4.6. Fabry Disease

16.8.2.4.7. Anthrax

16.8.2.4.8. Pompe Disease

16.8.2.4.9. Influenza

16.8.2.4.9.1. Type A

16.8.2.4.9.2. Type B

16.8.2.4.9.3. Type C

16.8.2.4.10. Alzheimer

16.8.2.4.11. Respiratory Syndromes

16.8.2.4.12. Gaucher disease

16.8.2.4.13. Cancer

16.8.2.4.14. Others

16.8.2.5. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.2.5.1. Intramuscular

16.8.2.5.2. Oral Administration

16.8.2.5.3. Others

16.8.2.6. Japan Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.2.6.1. Hospitals

16.8.2.6.2. Clinics

16.8.2.6.3. Primary Care Centers

16.8.2.6.4. Others

16.8.3. India

16.8.3.1. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.3.1.1. Phase I

16.8.3.1.2. Phase II

16.8.3.1.3. Others

16.8.3.2. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.3.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.3.2.2. Nicotiana benthamiana leaves

16.8.3.2.3. Carrot cell culture

16.8.3.2.4. Rice seeds

16.8.3.2.5. Moss

16.8.3.2.6. Algae

16.8.3.2.7. Duckweed LeafyBiomass

16.8.3.2.8. Others

16.8.3.3. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.3.3.1. Taliglucerase alfa

16.8.3.3.2. ZMApp

16.8.3.3.3. PRX-102

16.8.3.3.4. HAI-05

16.8.3.3.5. Others

16.8.3.4. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.3.4.1. HIV/AIDS

16.8.3.4.2. Ebola virus

16.8.3.4.3. Cholera

16.8.3.4.4. Leprosy

16.8.3.4.5. Tuberculosis

16.8.3.4.6. Fabry Disease

16.8.3.4.7. Anthrax

16.8.3.4.8. Pompe Disease

16.8.3.4.9. Influenza

16.8.3.4.9.1. Type A

16.8.3.4.9.2. Type B

16.8.3.4.9.3. Type C

16.8.3.4.10. Alzheimer

16.8.3.4.11. Respiratory Syndromes

16.8.3.4.12. Gaucher disease

16.8.3.4.13. Cancer

16.8.3.4.14. Others

16.8.3.5. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.3.5.1. Intramuscular

16.8.3.5.2. Oral Administration

16.8.3.5.3. Others

16.8.3.6. India Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.3.6.1. Hospitals

16.8.3.6.2. Clinics

16.8.3.6.3. Primary Care Centers

16.8.3.6.4. Others

16.8.4. New Zealand

16.8.4.1. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.4.1.1. Phase I

16.8.4.1.2. Phase II

16.8.4.1.3. Others

16.8.4.2. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.4.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.4.2.2. Nicotiana benthamiana leaves

16.8.4.2.3. Carrot cell culture

16.8.4.2.4. Rice seeds

16.8.4.2.5. Moss

16.8.4.2.6. Algae

16.8.4.2.7. Duckweed LeafyBiomass

16.8.4.2.8. Others

16.8.4.3. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.4.3.1. Taliglucerase alfa

16.8.4.3.2. ZMApp

16.8.4.3.3. PRX-102

16.8.4.3.4. HAI-05

16.8.4.3.5. Others

16.8.4.4. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.4.4.1. HIV/AIDS

16.8.4.4.2. Ebola virus

16.8.4.4.3. Cholera

16.8.4.4.4. Leprosy

16.8.4.4.5. Tuberculosis

16.8.4.4.6. Fabry Disease

16.8.4.4.7. Anthrax

16.8.4.4.8. Pompe Disease

16.8.4.4.9. Influenza

16.8.4.4.9.1. Type A

16.8.4.4.9.2. Type B

16.8.4.4.9.3. Type C

16.8.4.4.10. Alzheimer

16.8.4.4.11. Respiratory Syndromes

16.8.4.4.12. Gaucher disease

16.8.4.4.13. Cancer

16.8.4.4.14. Others

16.8.4.5. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.4.5.1. Intramuscular

16.8.4.5.2. Oral Administration

16.8.4.5.3. Others

16.8.4.6. New Zealand Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.4.6.1. Hospitals

16.8.4.6.2. Clinics

16.8.4.6.3. Primary Care Centers

16.8.4.6.4. Others

16.8.5. Australia

16.8.5.1. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.5.1.1. Phase I

16.8.5.1.2. Phase II

16.8.5.1.3. Others

16.8.5.2. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.5.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.5.2.2. Nicotiana benthamiana leaves

16.8.5.2.3. Carrot cell culture

16.8.5.2.4. Rice seeds

16.8.5.2.5. Moss

16.8.5.2.6. Algae

16.8.5.2.7. Duckweed LeafyBiomass

16.8.5.2.8. Others

16.8.5.3. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.5.3.1. Taliglucerase alfa

16.8.5.3.2. ZMApp

16.8.5.3.3. PRX-102

16.8.5.3.4. HAI-05

16.8.5.3.5. Others

16.8.5.4. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.5.4.1. HIV/AIDS

16.8.5.4.2. Ebola virus

16.8.5.4.3. Cholera

16.8.5.4.4. Leprosy

16.8.5.4.5. Tuberculosis

16.8.5.4.6. Fabry Disease

16.8.5.4.7. Anthrax

16.8.5.4.8. Pompe Disease

16.8.5.4.9. Influenza

16.8.5.4.9.1. Type A

16.8.5.4.9.2. Type B

16.8.5.4.9.3. Type C

16.8.5.4.10. Alzheimer

16.8.5.4.11. Respiratory Syndromes

16.8.5.4.12. Gaucher disease

16.8.5.4.13. Cancer

16.8.5.4.14. Others

16.8.5.5. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.5.5.1. Intramuscular

16.8.5.5.2. Oral Administration

16.8.5.5.3. Others

16.8.5.6. Australia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.5.6.1. Hospitals

16.8.5.6.2. Clinics

16.8.5.6.3. Primary Care Centers

16.8.5.6.4. Others

16.8.6. South Korea

16.8.6.1. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.6.1.1. Phase I

16.8.6.1.2. Phase II

16.8.6.1.3. Others

16.8.6.2. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.6.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.6.2.2. Nicotiana benthamiana leaves

16.8.6.2.3. Carrot cell culture

16.8.6.2.4. Rice seeds

16.8.6.2.5. Moss

16.8.6.2.6. Algae

16.8.6.2.7. Duckweed LeafyBiomass

16.8.6.2.8. Others

16.8.6.3. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.6.3.1. Taliglucerase alfa

16.8.6.3.2. ZMApp

16.8.6.3.3. PRX-102

16.8.6.3.4. HAI-05

16.8.6.3.5. Others

16.8.6.4. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.6.4.1. HIV/AIDS

16.8.6.4.2. Ebola virus

16.8.6.4.3. Cholera

16.8.6.4.4. Leprosy

16.8.6.4.5. Tuberculosis

16.8.6.4.6. Fabry Disease

16.8.6.4.7. Anthrax

16.8.6.4.8. Pompe Disease

16.8.6.4.9. Influenza

16.8.6.4.9.1. Type A

16.8.6.4.9.2. Type B

16.8.6.4.9.3. Type C

16.8.6.4.10. Alzheimer

16.8.6.4.11. Respiratory Syndromes

16.8.6.4.12. Gaucher disease

16.8.6.4.13. Cancer

16.8.6.4.14. Others

16.8.6.5. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.6.5.1. Intramuscular

16.8.6.5.2. Oral Administration

16.8.6.5.3. Others

16.8.6.6. South Korea Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.6.6.1. Hospitals

16.8.6.6.2. Clinics

16.8.6.6.3. Primary Care Centers

16.8.6.6.4. Others

16.8.7. Southeast Asia

16.8.7.1. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.7.1.1. Phase I

16.8.7.1.2. Phase II

16.8.7.1.3. Others

16.8.7.2. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.7.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.7.2.2. Nicotiana benthamiana leaves

16.8.7.2.3. Carrot cell culture

16.8.7.2.4. Rice seeds

16.8.7.2.5. Moss

16.8.7.2.6. Algae

16.8.7.2.7. Duckweed LeafyBiomass

16.8.7.2.8. Others

16.8.7.3. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.7.3.1. Taliglucerase alfa

16.8.7.3.2. ZMApp

16.8.7.3.3. PRX-102

16.8.7.3.4. HAI-05

16.8.7.3.5. Others

16.8.7.4. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.7.4.1. HIV/AIDS

16.8.7.4.2. Ebola virus

16.8.7.4.3. Cholera

16.8.7.4.4. Leprosy

16.8.7.4.5. Tuberculosis

16.8.7.4.6. Fabry Disease

16.8.7.4.7. Anthrax

16.8.7.4.8. Pompe Disease

16.8.7.4.9. Influenza

16.8.7.4.9.1. Type A

16.8.7.4.9.2. Type B

16.8.7.4.9.3. Type C

16.8.7.4.10. Alzheimer

16.8.7.4.11. Respiratory Syndromes

16.8.7.4.12. Gaucher disease

16.8.7.4.13. Cancer

16.8.7.4.14. Others

16.8.7.5. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.7.5.1. Intramuscular

16.8.7.5.2. Oral Administration

16.8.7.5.3. Others

16.8.7.6. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.7.6.1. Hospitals

16.8.7.6.2. Clinics

16.8.7.6.3. Primary Care Centers

16.8.7.6.4. Others

16.8.7.7. Southeast Asia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

16.8.7.7.1. Indonesia

16.8.7.7.2. Thailand

16.8.7.7.3. Malaysia

16.8.7.7.4. Singapore

16.8.7.7.5. Rest of Southeast Asia

16.8.8. Rest of Asia Pacific

16.8.8.1. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

16.8.8.1.1. Phase I

16.8.8.1.2. Phase II

16.8.8.1.3. Others

16.8.8.2. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

16.8.8.2.1. Tobacco, tobacco cells, tobacco leaves

16.8.8.2.2. Nicotiana benthamiana leaves

16.8.8.2.3. Carrot cell culture

16.8.8.2.4. Rice seeds

16.8.8.2.5. Moss

16.8.8.2.6. Algae

16.8.8.2.7. Duckweed LeafyBiomass

16.8.8.2.8. Others

16.8.8.3. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

16.8.8.3.1. Taliglucerase alfa

16.8.8.3.2. ZMApp

16.8.8.3.3. PRX-102

16.8.8.3.4. HAI-05

16.8.8.3.5. Others

16.8.8.4. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

16.8.8.4.1. HIV/AIDS

16.8.8.4.2. Ebola virus

16.8.8.4.3. Cholera

16.8.8.4.4. Leprosy

16.8.8.4.5. Tuberculosis

16.8.8.4.6. Fabry Disease

16.8.8.4.7. Anthrax

16.8.8.4.8. Pompe Disease

16.8.8.4.9. Influenza

16.8.8.4.9.1. Type A

16.8.8.4.9.2. Type B

16.8.8.4.9.3. Type C

16.8.8.4.10. Alzheimer

16.8.8.4.11. Respiratory Syndromes

16.8.8.4.12. Gaucher disease

16.8.8.4.13. Cancer

16.8.8.4.14. Others

16.8.8.5. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.8.8.5.1. Intramuscular

16.8.8.5.2. Oral Administration

16.8.8.5.3. Others

16.8.8.6. Rest of Asia Pacific Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.8.6.1. Hospitals

16.8.8.6.2. Clinics

16.8.8.6.3. Primary Care Centers

16.8.8.6.4. Others

16.9. Key Segment for Channeling Investments

16.9.1. By Country

16.9.2. By Clinical Trail

16.9.3. By Source

16.9.4. By Product

16.9.5. By Diseases

16.9.6. By Mode of Administration

16.9.7. By End Users

17. Middle East and Africa Plant-Based Biologics Market Analysis and Forecasts, 2020 - 2028

17.1. Overview

17.1.1. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn)

17.2. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.2.1. Phase I

17.2.2. Phase II

17.2.3. Others

17.3. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.3.1. Tobacco, tobacco cells, tobacco leaves

17.3.2. Nicotiana benthamiana leaves

17.3.3. Carrot cell culture

17.3.4. Rice seeds

17.3.5. Moss

17.3.6. Algae

17.3.7. Duckweed LeafyBiomass

17.3.8. Others

17.4. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.4.1. Taliglucerase alfa

17.4.2. ZMApp

17.4.3. PRX-102

17.4.4. HAI-05

17.4.5. Others

17.5. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.5.1. HIV/AIDS

17.5.2. Ebola virus

17.5.3. Cholera

17.5.4. Leprosy

17.5.5. Tuberculosis

17.5.6. Fabry Disease

17.5.7. Anthrax

17.5.8. Pompe Disease

17.5.9. Influenza

17.5.9.1. Type A

17.5.9.2. Type B

17.5.9.3. Type C

17.5.10. Alzheimer

17.5.11. Respiratory Syndromes

17.5.12. Gaucher disease

17.5.13. Cancer

17.5.14. Others

17.6. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.6.1. Intramuscular

17.6.2. Oral Administration

17.6.3. Others

17.7. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.7.1. Hospitals

17.7.2. Clinics

17.7.3. Primary Care Centers

17.7.4. Others

17.8. Middle East and Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

17.8.1. Saudi Arabia

17.8.1.1. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.1.1.1. Phase I

17.8.1.1.2. Phase II

17.8.1.1.3. Others

17.8.1.2. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.1.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.1.2.2. Nicotiana benthamiana leaves

17.8.1.2.3. Carrot cell culture

17.8.1.2.4. Rice seeds

17.8.1.2.5. Moss

17.8.1.2.6. Algae

17.8.1.2.7. Duckweed LeafyBiomass

17.8.1.2.8. Others

17.8.1.3. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.1.3.1. Taliglucerase alfa

17.8.1.3.2. ZMApp

17.8.1.3.3. PRX-102

17.8.1.3.4. HAI-05

17.8.1.3.5. Others

17.8.1.4. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.1.4.1. HIV/AIDS

17.8.1.4.2. Ebola virus

17.8.1.4.3. Cholera

17.8.1.4.4. Leprosy

17.8.1.4.5. Tuberculosis

17.8.1.4.6. Fabry Disease

17.8.1.4.7. Anthrax

17.8.1.4.8. Pompe Disease

17.8.1.4.9. Influenza

17.8.1.4.9.1. Type A

17.8.1.4.9.2. Type B

17.8.1.4.9.3. Type C

17.8.1.4.10. Alzheimer

17.8.1.4.11. Respiratory Syndromes

17.8.1.4.12. Gaucher disease

17.8.1.4.13. Cancer

17.8.1.4.14. Others

17.8.1.5. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.1.5.1. Intramuscular

17.8.1.5.2. Oral Administration

17.8.1.5.3. Others

17.8.1.6. Saudi Arabia Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.1.6.1. Hospitals

17.8.1.6.2. Clinics

17.8.1.6.3. Primary Care Centers

17.8.1.6.4. Others

17.8.2. UAE

17.8.2.1. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.2.1.1. Phase I

17.8.2.1.2. Phase II

17.8.2.1.3. Others

17.8.2.2. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.2.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.2.2.2. Nicotiana benthamiana leaves

17.8.2.2.3. Carrot cell culture

17.8.2.2.4. Rice seeds

17.8.2.2.5. Moss

17.8.2.2.6. Algae

17.8.2.2.7. Duckweed LeafyBiomass

17.8.2.2.8. Others

17.8.2.3. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.2.3.1. Taliglucerase alfa

17.8.2.3.2. ZMApp

17.8.2.3.3. PRX-102

17.8.2.3.4. HAI-05

17.8.2.3.5. Others

17.8.2.4. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.2.4.1. HIV/AIDS

17.8.2.4.2. Ebola virus

17.8.2.4.3. Cholera

17.8.2.4.4. Leprosy

17.8.2.4.5. Tuberculosis

17.8.2.4.6. Fabry Disease

17.8.2.4.7. Anthrax

17.8.2.4.8. Pompe Disease

17.8.2.4.9. Influenza

17.8.2.4.9.1. Type A

17.8.2.4.9.2. Type B

17.8.2.4.9.3. Type C

17.8.2.4.10. Alzheimer

17.8.2.4.11. Respiratory Syndromes

17.8.2.4.12. Gaucher disease

17.8.2.4.13. Cancer

17.8.2.4.14. Others

17.8.2.5. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.2.5.1. Intramuscular

17.8.2.5.2. Oral Administration

17.8.2.5.3. Others

17.8.2.6. UAE Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.2.6.1. Hospitals

17.8.2.6.2. Clinics

17.8.2.6.3. Primary Care Centers

17.8.2.6.4. Others

17.8.3. Egypt

17.8.3.1. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.3.1.1. Phase I

17.8.3.1.2. Phase II

17.8.3.1.3. Others

17.8.3.2. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.3.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.3.2.2. Nicotiana benthamiana leaves

17.8.3.2.3. Carrot cell culture

17.8.3.2.4. Rice seeds

17.8.3.2.5. Moss

17.8.3.2.6. Algae

17.8.3.2.7. Duckweed LeafyBiomass

17.8.3.2.8. Others

17.8.3.3. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.3.3.1. Taliglucerase alfa

17.8.3.3.2. ZMApp

17.8.3.3.3. PRX-102

17.8.3.3.4. HAI-05

17.8.3.3.5. Others

17.8.3.4. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.3.4.1. HIV/AIDS

17.8.3.4.2. Ebola virus

17.8.3.4.3. Cholera

17.8.3.4.4. Leprosy

17.8.3.4.5. Tuberculosis

17.8.3.4.6. Fabry Disease

17.8.3.4.7. Anthrax

17.8.3.4.8. Pompe Disease

17.8.3.4.9. Influenza

17.8.3.4.9.1. Type A

17.8.3.4.9.2. Type B

17.8.3.4.9.3. Type C

17.8.3.4.10. Alzheimer

17.8.3.4.11. Respiratory Syndromes

17.8.3.4.12. Gaucher disease

17.8.3.4.13. Cancer

17.8.3.4.14. Others

17.8.3.5. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.3.5.1. Intramuscular

17.8.3.5.2. Oral Administration

17.8.3.5.3. Others

17.8.3.6. Egypt Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.3.6.1. Hospitals

17.8.3.6.2. Clinics

17.8.3.6.3. Primary Care Centers

17.8.3.6.4. Others

17.8.4. Kuwait

17.8.4.1. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.4.1.1. Phase I

17.8.4.1.2. Phase II

17.8.4.1.3. Others

17.8.4.2. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.4.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.4.2.2. Nicotiana benthamiana leaves

17.8.4.2.3. Carrot cell culture

17.8.4.2.4. Rice seeds

17.8.4.2.5. Moss

17.8.4.2.6. Algae

17.8.4.2.7. Duckweed LeafyBiomass

17.8.4.2.8. Others

17.8.4.3. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.4.3.1. Taliglucerase alfa

17.8.4.3.2. ZMApp

17.8.4.3.3. PRX-102

17.8.4.3.4. HAI-05

17.8.4.3.5. Others

17.8.4.4. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.4.4.1. HIV/AIDS

17.8.4.4.2. Ebola virus

17.8.4.4.3. Cholera

17.8.4.4.4. Leprosy

17.8.4.4.5. Tuberculosis

17.8.4.4.6. Fabry Disease

17.8.4.4.7. Anthrax

17.8.4.4.8. Pompe Disease

17.8.4.4.9. Influenza

17.8.4.4.9.1. Type A

17.8.4.4.9.2. Type B

17.8.4.4.9.3. Type C

17.8.4.4.10. Alzheimer

17.8.4.4.11. Respiratory Syndromes

17.8.4.4.12. Gaucher disease

17.8.4.4.13. Cancer

17.8.4.4.14. Others

17.8.4.5. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.4.5.1. Intramuscular

17.8.4.5.2. Oral Administration

17.8.4.5.3. Others

17.8.4.6. Kuwait Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.4.6.1. Hospitals

17.8.4.6.2. Clinics

17.8.4.6.3. Primary Care Centers

17.8.4.6.4. Others

17.8.5. South Africa

17.8.5.1. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.5.1.1. Phase I

17.8.5.1.2. Phase II

17.8.5.1.3. Others

17.8.5.2. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.5.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.5.2.2. Nicotiana benthamiana leaves

17.8.5.2.3. Carrot cell culture

17.8.5.2.4. Rice seeds

17.8.5.2.5. Moss

17.8.5.2.6. Algae

17.8.5.2.7. Duckweed LeafyBiomass

17.8.5.2.8. Others

17.8.5.3. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.5.3.1. Taliglucerase alfa

17.8.5.3.2. ZMApp

17.8.5.3.3. PRX-102

17.8.5.3.4. HAI-05

17.8.5.3.5. Others

17.8.5.4. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.5.4.1. HIV/AIDS

17.8.5.4.2. Ebola virus

17.8.5.4.3. Cholera

17.8.5.4.4. Leprosy

17.8.5.4.5. Tuberculosis

17.8.5.4.6. Fabry Disease

17.8.5.4.7. Anthrax

17.8.5.4.8. Pompe Disease

17.8.5.4.9. Influenza

17.8.5.4.9.1. Type A

17.8.5.4.9.2. Type B

17.8.5.4.9.3. Type C

17.8.5.4.10. Alzheimer

17.8.5.4.11. Respiratory Syndromes

17.8.5.4.12. Gaucher disease

17.8.5.4.13. Cancer

17.8.5.4.14. Others

17.8.5.5. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.5.5.1. Intramuscular

17.8.5.5.2. Oral Administration

17.8.5.5.3. Others

17.8.5.6. South Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.5.6.1. Hospitals

17.8.5.6.2. Clinics

17.8.5.6.3. Primary Care Centers

17.8.5.6.4. Others

17.8.6. Rest of Middle East & Africa

17.8.6.1. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

17.8.6.1.1. Phase I

17.8.6.1.2. Phase II

17.8.6.1.3. Others

17.8.6.2. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

17.8.6.2.1. Tobacco, tobacco cells, tobacco leaves

17.8.6.2.2. Nicotiana benthamiana leaves

17.8.6.2.3. Carrot cell culture

17.8.6.2.4. Rice seeds

17.8.6.2.5. Moss

17.8.6.2.6. Algae

17.8.6.2.7. Duckweed LeafyBiomass

17.8.6.2.8. Others

17.8.6.3. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

17.8.6.3.1. Taliglucerase alfa

17.8.6.3.2. ZMApp

17.8.6.3.3. PRX-102

17.8.6.3.4. HAI-05

17.8.6.3.5. Others

17.8.6.4. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

17.8.6.4.1. HIV/AIDS

17.8.6.4.2. Ebola virus

17.8.6.4.3. Cholera

17.8.6.4.4. Leprosy

17.8.6.4.5. Tuberculosis

17.8.6.4.6. Fabry Disease

17.8.6.4.7. Anthrax

17.8.6.4.8. Pompe Disease

17.8.6.4.9. Influenza

17.8.6.4.9.1. Type A

17.8.6.4.9.2. Type B

17.8.6.4.9.3. Type C

17.8.6.4.10. Alzheimer

17.8.6.4.11. Respiratory Syndromes

17.8.6.4.12. Gaucher disease

17.8.6.4.13. Cancer

17.8.6.4.14. Others

17.8.6.5. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

17.8.6.5.1. Intramuscular

17.8.6.5.2. Oral Administration

17.8.6.5.3. Others

17.8.6.6. Rest of Middle East & Africa Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.6.6.1. Hospitals

17.8.6.6.2. Clinics

17.8.6.6.3. Primary Care Centers

17.8.6.6.4. Others

17.9. Key Segment for Channeling Investments

17.9.1. By Country

17.9.2. By Clinical Trail

17.9.3. By Source

17.9.4. By Product

17.9.5. By Diseases

17.9.6. By Mode of Administration

17.9.7. By End Users

18. Latin America Plant-Based Biologics Market Analysis and Forecasts, 2020 - 2028

18.1. Overview

18.1.1. Latin America Plant-Based Biologics Market Revenue (US$ Mn)

18.2. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

18.2.1. Phase I

18.2.2. Phase II

18.2.3. Others

18.3. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

18.3.1. Tobacco, tobacco cells, tobacco leaves

18.3.2. Nicotiana benthamiana leaves

18.3.3. Carrot cell culture

18.3.4. Rice seeds

18.3.5. Moss

18.3.6. Algae

18.3.7. Duckweed LeafyBiomass

18.3.8. Others

18.4. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

18.4.1. Taliglucerase alfa

18.4.2. ZMApp

18.4.3. PRX-102

18.4.4. HAI-05

18.4.5. Others

18.5. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

18.5.1. HIV/AIDS

18.5.2. Ebola virus

18.5.3. Cholera

18.5.4. Leprosy

18.5.5. Tuberculosis

18.5.6. Fabry Disease

18.5.7. Anthrax

18.5.8. Pompe Disease

18.5.9. Influenza

18.5.9.1. Type A

18.5.9.2. Type B

18.5.9.3. Type C

18.5.10. Alzheimer

18.5.11. Respiratory Syndromes

18.5.12. Gaucher disease

18.5.13. Cancer

18.5.14. Others

18.6. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

18.6.1. Intramuscular

18.6.2. Oral Administration

18.6.3. Others

18.7. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

18.7.1. Hospitals

18.7.2. Clinics

18.7.3. Primary Care Centers

18.7.4. Others

18.8. Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Country

18.8.1. Brazil

18.8.1.1. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

18.8.1.1.1. Phase I

18.8.1.1.2. Phase II

18.8.1.1.3. Others

18.8.1.2. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

18.8.1.2.1. Tobacco, tobacco cells, tobacco leaves

18.8.1.2.2. Nicotiana benthamiana leaves

18.8.1.2.3. Carrot cell culture

18.8.1.2.4. Rice seeds

18.8.1.2.5. Moss

18.8.1.2.6. Algae

18.8.1.2.7. Duckweed LeafyBiomass

18.8.1.2.8. Others

18.8.1.3. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

18.8.1.3.1. Taliglucerase alfa

18.8.1.3.2. ZMApp

18.8.1.3.3. PRX-102

18.8.1.3.4. HAI-05

18.8.1.3.5. Others

18.8.1.4. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

18.8.1.4.1. HIV/AIDS

18.8.1.4.2. Ebola virus

18.8.1.4.3. Cholera

18.8.1.4.4. Leprosy

18.8.1.4.5. Tuberculosis

18.8.1.4.6. Fabry Disease

18.8.1.4.7. Anthrax

18.8.1.4.8. Pompe Disease

18.8.1.4.9. Influenza

18.8.1.4.9.1. Type A

18.8.1.4.9.2. Type B

18.8.1.4.9.3. Type C

18.8.1.4.10. Alzheimer

18.8.1.4.11. Respiratory Syndromes

18.8.1.4.12. Gaucher disease

18.8.1.4.13. Cancer

18.8.1.4.14. Others

18.8.1.5. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

18.8.1.5.1. Intramuscular

18.8.1.5.2. Oral Administration

18.8.1.5.3. Others

18.8.1.6. Brazil Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.1.6.1. Hospitals

18.8.1.6.2. Clinics

18.8.1.6.3. Primary Care Centers

18.8.1.6.4. Others

18.8.2. Argentina

18.8.2.1. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

18.8.2.1.1. Phase I

18.8.2.1.2. Phase II

18.8.2.1.3. Others

18.8.2.2. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

18.8.2.2.1. Tobacco, tobacco cells, tobacco leaves

18.8.2.2.2. Nicotiana benthamiana leaves

18.8.2.2.3. Carrot cell culture

18.8.2.2.4. Rice seeds

18.8.2.2.5. Moss

18.8.2.2.6. Algae

18.8.2.2.7. Duckweed LeafyBiomass

18.8.2.2.8. Others

18.8.2.3. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

18.8.2.3.1. Taliglucerase alfa

18.8.2.3.2. ZMApp

18.8.2.3.3. PRX-102

18.8.2.3.4. HAI-05

18.8.2.3.5. Others

18.8.2.4. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

18.8.2.4.1. HIV/AIDS

18.8.2.4.2. Ebola virus

18.8.2.4.3. Cholera

18.8.2.4.4. Leprosy

18.8.2.4.5. Tuberculosis

18.8.2.4.6. Fabry Disease

18.8.2.4.7. Anthrax

18.8.2.4.8. Pompe Disease

18.8.2.4.9. Influenza

18.8.2.4.9.1. Type A

18.8.2.4.9.2. Type B

18.8.2.4.9.3. Type C

18.8.2.4.10. Alzheimer

18.8.2.4.11. Respiratory Syndromes

18.8.2.4.12. Gaucher disease

18.8.2.4.13. Cancer

18.8.2.4.14. Others

18.8.2.5. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

18.8.2.5.1. Intramuscular

18.8.2.5.2. Oral Administration

18.8.2.5.3. Others

18.8.2.6. Argentina Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.2.6.1. Hospitals

18.8.2.6.2. Clinics

18.8.2.6.3. Primary Care Centers

18.8.2.6.4. Others

18.8.3. Rest of Latin America

18.8.3.1. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Clinical Trail

18.8.3.1.1. Phase I

18.8.3.1.2. Phase II

18.8.3.1.3. Others

18.8.3.2. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Source

18.8.3.2.1. Tobacco, tobacco cells, tobacco leaves

18.8.3.2.2. Nicotiana benthamiana leaves

18.8.3.2.3. Carrot cell culture

18.8.3.2.4. Rice seeds

18.8.3.2.5. Moss

18.8.3.2.6. Algae

18.8.3.2.7. Duckweed LeafyBiomass

18.8.3.2.8. Others

18.8.3.3. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Product

18.8.3.3.1. Taliglucerase alfa

18.8.3.3.2. ZMApp

18.8.3.3.3. PRX-102

18.8.3.3.4. HAI-05

18.8.3.3.5. Others

18.8.3.4. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Diseases

18.8.3.4.1. HIV/AIDS

18.8.3.4.2. Ebola virus

18.8.3.4.3. Cholera

18.8.3.4.4. Leprosy

18.8.3.4.5. Tuberculosis

18.8.3.4.6. Fabry Disease

18.8.3.4.7. Anthrax

18.8.3.4.8. Pompe Disease

18.8.3.4.9. Influenza

18.8.3.4.9.1. Type A

18.8.3.4.9.2. Type B

18.8.3.4.9.3. Type C

18.8.3.4.10. Alzheimer

18.8.3.4.11. Respiratory Syndromes

18.8.3.4.12. Gaucher disease

18.8.3.4.13. Cancer

18.8.3.4.14. Others

18.8.3.5. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

18.8.3.5.1. Intramuscular

18.8.3.5.2. Oral Administration

18.8.3.5.3. Others

18.8.3.6. Rest of Latin America Plant-Based Biologics Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.3.6.1. Hospitals

18.8.3.6.2. Clinics

18.8.3.6.3. Primary Care Centers

18.8.3.6.4. Others

18.9. Key Segment for Channeling Investments

18.9.1. By Country

18.9.2. By Clinical Trail

18.9.3. By Source

18.9.4. By Product

18.9.5. By Diseases

18.9.6. By Mode of Administration

18.9.7. By End Users

19. Competitive Benchmarking

19.1. Market Share Analysis, 2019

19.2. Global Presence and Growth Strategies

19.2.1. Mergers and Acquisitions

19.2.2. Product Launches

19.2.3. Investments Trends

19.2.4. R&D Initiatives

20. Player Profiles

20.1. Byondis

20.1.1. Company Details

20.1.2. Company Overview

20.1.3. Product Offerings

20.1.4. Key Developments

20.1.5. Financial Analysis

20.1.6. SWOT Analysis

20.1.7. Business Strategies

20.2. eleva GmbH

20.2.1. Company Details

20.2.2. Company Overview

20.2.3. Product Offerings

20.2.4. Key Developments

20.2.5. Financial Analysis

20.2.6. SWOT Analysis

20.2.7. Business Strategies

20.3. Eversea Inc.

20.3.1. Company Details

20.3.2. Company Overview

20.3.3. Product Offerings

20.3.4. Key Developments

20.3.5. Financial Analysis

20.3.6. SWOT Analysis

20.3.7. Business Strategies

20.4. iBio, Inc.

20.4.1. Company Details

20.4.2. Company Overview

20.4.3. Product Offerings

20.4.4. Key Developments

20.4.5. Financial Analysis

20.4.6. SWOT Analysis

20.4.7. Business Strategies

20.5. Icon Genetics GmbH

20.5.1. Company Details

20.5.2. Company Overview

20.5.3. Product Offerings

20.5.4. Key Developments

20.5.5. Financial Analysis

20.5.6. SWOT Analysis

20.5.7. Business Strategies

20.6. InVitria

20.6.1. Company Details

20.6.2. Company Overview

20.6.3. Product Offerings

20.6.4. Key Developments

20.6.5. Financial Analysis

20.6.6. SWOT Analysis

20.6.7. Business Strategies

20.7. Kentucky BioProcessing, Inc.

20.7.1. Company Details

20.7.2. Company Overview

20.7.3. Product Offerings

20.7.4. Key Developments

20.7.5. Financial Analysis

20.7.6. SWOT Analysis

20.7.7. Business Strategies

20.8. Leaf Expression Systems

20.8.1. Company Details

20.8.2. Company Overview

20.8.3. Product Offerings

20.8.4. Key Developments

20.8.5. Financial Analysis

20.8.6. SWOT Analysis

20.8.7. Business Strategies

20.9. Mapp Biopharmaceutical, Inc.

20.9.1. Company Details

20.9.2. Company Overview

20.9.3. Product Offerings

20.9.4. Key Developments

20.9.5. Financial Analysis

20.9.6. SWOT Analysis

20.9.7. Business Strategies

20.10. Medicago Inc.

20.10.1. Company Details

20.10.2. Company Overview

20.10.3. Product Offerings

20.10.4. Key Developments

20.10.5. Financial Analysis

20.10.6. SWOT Analysis

20.10.7. Business Strategies

20.11. OnePointOne, Inc.

20.11.1. Company Details

20.11.2. Company Overview

20.11.3. Product Offerings

20.11.4. Key Developments

20.11.5. Financial Analysis

20.11.6. SWOT Analysis

20.11.7. Business Strategies

20.12. Pfizer Inc.

20.12.1. Company Details

20.12.2. Company Overview

20.12.3. Product Offerings

20.12.4. Key Developments

20.12.5. Financial Analysis

20.12.6. SWOT Analysis

20.12.7. Business Strategies

20.13. Planet Biotechnology Inc.

20.13.1. Company Details

20.13.2. Company Overview

20.13.3. Product Offerings

20.13.4. Key Developments

20.13.5. Financial Analysis

20.13.6. SWOT Analysis

20.13.7. Business Strategies

20.14. PlantForm

20.14.1. Company Details

20.14.2. Company Overview

20.14.3. Product Offerings

20.14.4. Key Developments

20.14.5. Financial Analysis

20.14.6. SWOT Analysis

20.14.7. Business Strategies

20.15. Protalix Biotherapeutics

20.15.1. Company Details

20.15.2. Company Overview

20.15.3. Product Offerings

20.15.4. Key Developments

20.15.5. Financial Analysis

20.15.6. SWOT Analysis

20.15.7. Business Strategies

20.16. Ventria Bioscience Inc.

20.16.1. Company Details

20.16.2. Company Overview

20.16.3. Product Offerings

20.16.4. Key Developments

20.16.5. Financial Analysis

20.16.6. SWOT Analysis

20.16.7. Business Strategies

20.17. Zea Biosciences

20.17.1. Company Details

20.17.2. Company Overview

20.17.3. Product Offerings

20.17.4. Key Developments

20.17.5. Financial Analysis

20.17.6. SWOT Analysis

20.17.7. Business Strategies

20.18. Other Market Participants

21. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $4600

Multi users $8200

Global users $9100

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com